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The ability to edit the genome of organism can positively impact biomedical research. 
Using genome editing we can dissect the function of gene(s) and their regulatory elements 
and, more importantly, facilitate modelling of human genetic diseases to understand their 
pathology and develop treatments. The recently developed CRISPR/Cas9 genome editing 
platform has become rapidly and widely used in biomedical research due to its ease of use, 
highly efficiency and low cost. The research conducted during my PhD attempted to 
further develop this technology and apply it to a range of biological questions that are of 
interest to the Thomas laboratory.  
I showed that this technology can be applied to generate a gene-swap mouse model to 
study functional redundancy between closely related transcription factors in SOXB1 
family, SOX2 and SOX3. By swapping Sox3 with Sox2 in vivo we showed that the 
presence of Sox2 in the absence of Sox3 rescues Sox3-null phenotypes. This finding 
provides strong and direct evidence that they are functionally redundant. I also develop 
CRISPR/Cas9-based strategies to allow targeted elimination of an entire chromosome. 
These strategies termed centromere removal and chromosome shredding could facilitate 
efficient chromosome deletion as shown by successful elimination of the Y chromosome in 
mouse ES cells and zygotes.  
We also contribute to the development of CRISPR/Cas9 toolbox by generating plasmids 
that can express dual gRNAs and other required components such as the Cas9 or Cas9-
nickase as well as selection markers within a single plasmid. Interestingly, our vector 
design allows facile generation of two unique guides in a simple one-step reaction, 
rendering these plasmids user-friendly for researchers requiring simultaneous expression of 
two gRNAs. Targeting two sites can be achieved with very high efficiency using these 





repository. Lastly, my research show that large deletions are frequently generated as the 
repair outcome of CRISPR/Cas9-mediated cleavage. The large deletions contain mostly 
microhomology sequences at the break junctions and are generated via DNA resection, 
indicating an alternative end joining mechanism underlies their generation. This study 
reveals an underestimated yet common repair outcome that researchers should be aware of 
to avoid genotyping misinterpretation. 
Collectively, the studies in this thesis have contributed to the development of 
CRISPR/Cas9 genome editing technology by providing valuable tools and new knowledge 
about DNA repair. In addition, I demonstrate that CRISPR/Cas9 technology can be applied 
to diverse biological questions including functional redundancy of developmental 
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1.1. Genome editing 
Genome editing refers to the process of modifying (deleting, inserting or substituting) the 
genomic DNA sequence from its original form. This ability to modify genomic sequences 
is crucial for life science research. It can be used to mimic human diseases driven by 
genetic changes in cell lines and animal models, thereby increasing our understanding of 
the basic science of these diseases so that therapeutic options can be developed. Genomic 
modifications allow scientists to knock out genes or delete genetic elements to study their 
functions in biological systems. In an advanced form, genome editing can be used for 
therapy of diseases such as cancers, infectious and genetic diseases. Genome editing in the 
farming and crop industries can result in increased production by manipulating genes to 
generate plants or animals that are resistant to infection, can be harvested earlier or 
produce greater yields [1-8]. 
DNA modification in cells began decades ago with a method known as ‘gene targeting’, 
which takes advantage of the natural homologous recombination process. In gene 
targeting, exogenous DNA sequences are integrated into the desired genomic location by 
providing them with DNA donor containing sequences homologous to the DNA target. 
This technique has revolutionised biological research as it can be used in embryonic stem 
(ES) cells, and the genetically modified ES cells can be implanted into embryos to 
ultimately generate mutant animals. Many gene functions have been revealed by this 
technique. However, the gene targeting process is complicated. The incidence of targeted 
homologous recombination is very low (1 in 106–109 cells). Generation of genetically 
modified animals also requires multiple steps, which are prone to failure. Overall, this 
technique is time-consuming and costly, which hampers its use in research [4, 9]. 
Experiments with endonucleases have provided the insight that site-specific double strand 





at the break sites. More importantly, if exogenous DNA donor is provided while the DSB 
is present, the donor DNA can be integrated into the break sites more efficiently through 
the homology-directed repair (HDR) mechanism, allowing specific modification of DNA 
sequences (as is also the case for gene targeting). Given the importance of genome editing, 
scientists have been developing site-specific endonucleases to allow the efficient targeted 
modification of DNA sequences. To date, there are at least three major technologies that 
have been generated for this purpose: zinc finger nuclease (ZFN), transcription activator-
like effector nuclease (TALEN) and clustered regularly interspaced short palindromic 
repeats (CRISPR) [1-7] 
ZFN and TALEN recognise specific sequences through protein-DNA binding interactions 
via their DNA binding domains, which are customisable to enable the targeting of specific 
sequences (Figure 1.1). Their DNA binding domains consist of modules, with each module 
binding to specific nucleotides. Each module of ZFN or TALEN recognises three or one 
nucleotides respectively, and must be assembled in an order that corresponds to the target 
sequence. By fusing these sequence-specific binding domains to the dimer-dependent Fok1 
nuclease domain, ZFN and TALEN can induce site-specific DNA cleavage. This involves 
dimerisation of Fok1 to induce DNA breaks; therefore, to target as specific site for 
cleavage, a pair of ZFN or TALEN molecules with the correct orientation and spacing is 
required (Figure 1.1). Both ZFN and TALEN have been shown to efficiently induce 
targeted DNA DSBs for genome editing purposes. However, designing sequence-specific 
binding modules for ZFN is complicated and expensive. TALEN design is easier, but 
synthesising its modules is still costly. Due to this complexity, both technologies are 
almost impossible to use for multiplex targeting of different sites. Furthermore, they are 








Figure 1.1 | Major players in genome editing technologies: ZFN, TALEN and 
CRISPR/Cas9. ZFN and TALEN rely on proteins to bind to specific sequences. DSB are 
achieved through dimerisation of the Fok1 nuclease. CRISPR/Cas9 technology uses short 









On the other hand, the recently developed CRISPR/Cas system uses RNA:DNA Watson-
Crick base pairing to provide specificity (Figure 1.1). The endonuclease, Cas9, induces 
highly efficient DSBs to DNA target sequences by forming a complex with a short RNA 
molecule termed the guide-RNA (gRNA), that acts to guide Cas9 to target sequences. This 
makes genome editing much simpler because different genomic sites can be targeted for 
cleavage simply by changing the gRNA sequence. Furthermore, multiple gRNAs can be 
expressed or produced easily, which allows multiplex targeting of genomic regions. This 
versatility has made CRISPR/Cas9 technology a favourite tool for genome editing, and has 
revolutionised the genome engineering field. The simplicity of this system has attracted 
many researchers to this technology to study gene function or for other purposes, which 
has led to many CRISPR-related publications being produced (Figure 1.2) [1-7]. 
 
 
Figure 1.2 | Number of publications produced describing the use of ZFN, TALEN and 
CRISPR/Cas9 technologies. CRISPR/Cas9 technology has been rapidly adopted by 
researchers and has generated many publications over the past few years. Adapted from 






1.2. CRISPR/Cas9 technology 
CRISPR is an adaptive immune system found in prokaryotes. It was noted many years ago 
when scientists observed that Escherichia coli bacteria contained repetitive sequences 
separated by non-repetitive sequences, although they did not understand the function of 
these sequences [10]. As more sequencing data became available, scientists noticed that 
these clustered repeat elements were surprisingly common in bacteria and archaea 
genomes. More than 40% of bacteria and >90% of archaea have these clustered repeat 
elements, which were later named CRISPR [11, 12]. 
CRISPR loci contain an array of repeat sequences separated by spacer sequences and genes 
called Cas (CRISPR-associated) genes, which are mostly located adjacent to the CRISPR 
elements [12]. The spacer sequences were found to be short DNA sequences found in 
phage, which were acquired and integrated into CRISPR loci during the 
adaptation/immunisation process (Figure 1.3) [13-15]. In Type II CRISPR systems, such as 
that of Streptococcus pyogenes (Sp), the CRISPR array is transcribed as a single long 
transcript called pre-crRNA and then converted to several small CRISPR-RNA (crRNAs) 
by RNase III, where each single crRNA targets a unique foreign sequence complementary 
to the spacer sequences. To cleave the invader’s DNA, this crRNA requires two more 
components: Cas9 as the endonuclease and a trans-activating crRNA or tracrRNA, which 
forms a complex with the crRNAs to guide and activate the Cas9 endonuclease (Figure 
1.3). Notably, Cas9 can only cleave DNA when the target sequences contain a certain 
PAM (protospacer adjacent motif) adjacent to the foreign DNA target sequence (the PAM 
for Streptococcus pyogenes Cas9 or SpCas9 is NGG). This PAM requirement is crucial for 
the prokaryote CRISPR/Cas9 system to distinguish between the foreign DNA target and 
their own CRISPR arrays [13, 16-22]. In the genome, the crRNA-tracrRNA-Cas9 complex 





the PAM is recognised by the complex, it then interrogates the DNA target sequences for 
complementarity with the gRNA sequences, starting from the sequences adjacent to the 
PAM followed by the remaining sequences in a sequential manner (‘zip-up’ mechanism). 
Binding to the PAM and the complementarity of crRNA-DNA target will activate the 
nuclease activity of Cas9 and induce DNA cleavage facilitated by two nuclease domains, 
HNH and RuvC, which generate a DSB at a position three nucleotides distal to the PAM 
sequence [23-25]. 
In 2012, Jinek et al. [26] showed that they could adapt the CRISPR/Cas9 system from 
Streptococcus pyogenes to cleave DNA in vitro. Six months after this publication, in 2013, 
Cong et al. and Mali et al. [27, 28] published their work showing this system could induce 
targeted cleavage of DNA in vivo in mammalian genomes and that they would be useful 
for genome editing applications. These studies all also indicated that the three components 
required for the CRISPR/Cas9 system (crRNA-tracrRNA-Cas9) could be simplified to two 
components by merging the crRNA and tracrRNA into a single guide RNA (gRNA) 
(Figure 1.4). This single gRNA of the SpCas9 system consists of ~100 nt with the first ~20 
nt providing DNA target specificity. This means that targeting different target sequences 
requires alteration of only these ~20 nt, which can be easily performed using standard 
molecular biological techniques. Moreover, RNAs of this size can also be synthesised 
enzymatically or chemically. Currently, many vectors for performing genome editing using 
the CRISPR/Cas9 system are available and can be obtained easily through plasmid 
repositories such as Addgene (https://www.addgene.org/crispr/). Some of those vectors 
have been designed to be user-friendly; for example, by having ‘golden gate’ sites to 
simplify the generation of gRNAs of interest through the ‘golden gate’ cloning strategy 
[27, 29]. The choice of target sequences is also flexible as DNA target screening is only 





The simplicity of the Streptococcus pyogenes CRISPR/Cas9 system has made this 




Figure 1.3 | Mechanism of CRISPR adaptation and immunity in bacteria with a Type 
II CRISPR locus. During adaptation, invading viral sequences are cleaved and the 
resulting sequences are inserted as spacers between CRISPR repetitive sequences. When 
the bacterium is infected by the same virus, this CRISPR array is transcribed, producing 
RNAs that guide Cas9 endonuclease to cleave the viral DNA sequences. Adapted from 






organisms for a range of applications. Organisms that have been modified via 
CRISPR/Cas9 include mice, rats, rabbits, non-human primates, fish, farm animals, plants, 
yeast, bacteria, and controversially, human embryos [1, 2, 30-32]. 
 
1.3. Editing strategies using the CRISPR/Cas9 system 
Once CRISPR/Cas9 generates DSBs, the cellular DNA repair system immediately fixes the 
breaks. The primary repair pathway is non-homologous end joining (NHEJ), which results 
in precise joining of the breaks and therefore is non-mutagenic [33, 34]. However, in the 
case of endonuclease-mediated DSBs, these error-free ligations will be continuously 
cleaved by the endonucleases (when they are still present) as they are still recognised by 
the endonuclease as their target for cleavage. Cleavage and repair will endure until the 
endonucleases are no longer present or the target sequences are modified (through mis-
repair) and not recognised by the endonuclease. The DNA modifications in NHEJ usually 
produce small deletions (<20 bp) and/or small insertions (indels) at the site of the breaks, 
which are thought to occur randomly (Figure 1.4) [5, 27, 29, 35, 36]. These indel mutations 
potentially generate frameshift alleles that are useful for knocking out genes or can be used 
to disrupt protein binding sites or other DNA elements. In brief, the NHEJ mechanism 
involves high-affinity binding of the Ku70/Ku80 heterodimer to DSB to protect the DNA 
ends from degradation and to recruit other factors, such as DNA-PKcs. The MRN complex 
is also recruited to the break site together with Artemis to allow modification of the DNA 
ends. Finally, DNA ligase IV, together with XRRC4 and XLF, ligate the breaks [34, 37]. 
Interestingly, if a single break from a gRNA/Cas9 induces a small indel mutation, a pair of 
DNA breaks generated using two gRNAs flanking a sequence region may result in the 
deletion of the intervening sequence when the NHEJ process joins the distal ends [38-41]. 





manner. To date this approach has been used to delete sequences of up to 30 Mb [42]. 
Occasionally, the intervening sequences re-ligate back in the reverse orientation, creating 
inversions of the DNA region, which may be useful to model diseases caused by 
chromosomal inversions [40, 41, 43, 44]. In addition to generating large deletions and 
inversions, two simultaneous breaks can also induce chromosome translocations when the 
breaks are induced in two different chromosomes [43, 45, 46]. 
Recent studies have indicated that the distribution of small indels after CRISPR/Cas9 
breaks are not random, as was previously thought, but that this is influenced by the 
sequences around the Cas9 target sites. These non-random repair outcomes presumably 
result from both NHEJ and micro-homology end joining (MMEJ) repair mechanisms. The 
distribution of indels can thus be perturbed by inhibition of factors involved in NHEJ or 
MMEJ [47]. The MMEJ mechanism (sometimes called alternative end joining/Alt-EJ) is 
distinct from NHEJ. In MMEJ, DNA breaks are followed by 5’–3’ end resections 
generating single-stranded overhangs at both broken ends. The overhangs anneal to each 
other through their micro-homology sequences (1–16 nt), followed by DNA extension and 
ligation processes that result in the deletion of the sequences between the micro-
homologies, along with the micro-homology sequence from one side. Since the micro-
homology sequences engage during MMEJ, the product of this repair process is relatively 
predictable (Figure 1.4) [48, 49]. 
Specific changes in DNA sequences can be accomplished by providing a single-stranded 
oligodeoxynucleotide (ssODN) donor containing the intended sequence change flanked by 
homology sequences. Broken DNA will use this oligo donor as an HDR template, 
presumably via the same pathway as the single strand annealing (SSA) mechanism. The 
SSA mechanism is similar to MMEJ; however, DNA synapse/annealing after DNA 





sequences of ssODN commonly used for genome editing is usually around 40–80 nt, 
although shorter homology sequences of 20–35 nt can still be used as efficient HDR 
templates (Figure 1.4) [35, 50-52]. This ssODN donor approach has been shown to be 
efficient for inducing intended changes. To date, the maximum size of commercially 
available synthetic oligonucleotides is ~200 nt, which is sufficient when attempting to 
perform substitutions of a few base pairs or inserting short sequences such as LoxP and 
HA/Flag tag sequences [29, 51]. However, this size limitation restricts the insertion of 
longer sequences. Insertion of long sequences is usually done by providing a double-
stranded DNA (dsDNA) donor with long homology arms in the expectation that DNA 
repair employs the homologous recombination (HR) pathway and uses the donor as the HR 
template (Figure 1.4). The HR repair mechanism is an error-free repair pathway available 
in cellular systems. In natural HR, a DSB in one copy of a chromosome will be repaired 
using the sister chromatid as the repair template which is known as inter-homologue repair. 
The DSB will be followed by 5’–3’ long resection of DNA, generating 3’ overhangs that 
will search, invade and bind to the complementary sequences from the sister chromosome. 
After strand invasion, the broken string will be extended by polymerase, which copies the 
sequence of the sister chromatid before ligation, thus maintaining the integrity of the 
sequences [53]. The dsDNA donor for HR is co-transfected as a plasmid or a viral vector 
containing long homology sequences (usually >500 bp). However, the efficiency of this 
dsDNA donor approach is very low [29, 51, 54]. Inter-homologue repair itself can also be 
utilised to edit an allele in cells with heterozygous alleles by specifically targeting the to-
be-modified allele for cleavage while leaving another allele intact, thus the broken allele 
can use the sister chromatid as the repair template [32, 55]. 
Given that ssODN donors are much more efficient for performing insertions, scientists 
have been interested in performing insertions of long sequences using long single-stranded 





be generated using techniques such as reverse transcriptase- or nicking endonuclease-based 
techniques. This long ssDNA approach has been shown to efficiently induce the insertion 
of long DNA fragments [56, 57]. 
Knocking-in large inserts using dsDNA donors can also take advantage of efficient MMEJ 
repair. This method, known as PITCh (precise integration into target chromosome), 
designs the dsDNA donor to contain short homology arms (~20 bp) (Figure 1.4). Delivery 
of dsDNA donors relies on a circular plasmid that is also cleaved by CRISPR/Cas9 at the 
end of the homology arms. Simultaneous DSBs to the insertion site and the PITCh donor 
result in efficient PITCh donor integration to the target region via the MMEJ mechanism 
[58, 59]. 
A recent study has shown that inserting long DNA sequences can be achieved efficiently 
by providing dsDNA donors without homology sequences. This homology-independent 
technique, called HITI (homology-independent targeted integration), harnesses the 
efficient NHEJ repair pathway to join a linear dsDNA donor to break sites (Figure 1.4). 
These researchers showed that this technique is more efficient than the HR-based dsDNA 
donor system (with long homology arms) and the PITCh technique. As the NHEJ repair 
pathway is available in non-dividing cells, this technique is useful to correct mutations 
requiring DNA insertions in vivo in adult tissues where most cells no longer divide [60]. 
All intended changes by co-delivery of ssDNA or dsDNA donors should always consider 
the ability of CRISPR/Cas9 to re-cleave the same or similar target sequences. Therefore, 
the final DNA sequences after the knock-in should not contain target sequences, for 
instance, by altering the PAM to sequences that are not recognisable by Cas9, or by 
creating more mismatches to the new sequences to abolish the binding ability of gRNAs to 







Figure 1.4 | Genome editing strategies using the CRISPR/Cas9 system. DSBs, 
including those generated by Cas9, are repaired using pathways that either require DNA 
end resection (right box) or DNA end protection (left box). Repair by NHEJ will generate 
small indels (red highlights). dsDNA donor can be inserted to the breaks by the HITI 
technique. The pathway with resection can be repaired by MMEJ if the breaks occur 
between micro-homologies (black highlights), or by SSA if long repeat sequences are 
present (yellow highlights). The ssODN (oligo) donor can be efficiently inserted through 
the same mechanism as SSA. dsDNA can act as a donor template through the HR 





1.4. Delivery of CRISPR/Cas9 components 
The CRISPR/Cas9 components, gRNA and Cas9, can be delivered to cells in the form of 
DNA (plasmid, viral vector), RNA or RNP (ribonucleoproteins). Delivery of 
CRISPR/Cas9 components can be accomplished in various ways depending on the type of 
experiment and its purpose. Transfections (including electroporation) or transductions of 
gRNA and Cas9 in DNA form are commonly performed for editing genomic DNA of cells 
in culture (Figure 1.5C). The vectors expressing the Cas9 and gRNA may also contain 
selection markers, such as drug resistance or fluorescent markers, to allow for enrichment 
of successfully transfected cells and thereby increase efficiency. DNA donor template can 
be co-transfected when performing HDR. Some researchers prefer transfection in RNA or 
RNP form for various reasons, even though this technique does not use selection markers 
[29, 61, 62]. 
CRISPR/Cas9 components (including the DNA donor) can also be microinjected to the 
cytoplasm or pronucleus of fertilised eggs, as is commonly performed when generating 
mice carrying mutations (Figure 1.5D) [35, 51, 54]. Microinjection requires expensive 
apparatus and highly skilled technicians. Recent advances allow the generation of 
CRISPR/Cas9-mediated mutant mice without microinjection. These techniques involve 
electroporation of CRISPR/Cas9 components into mouse zygotes in a culture dish before 
implantation into the uterus or direct electroporation of embryos within the intact mouse 
oviduct [63-65]. Electroporation can also be performed on developing mouse embryos for 
tissue/organ specific genomic modifications, particularly in the brain, by a technique called 
in utero electroporation [60, 66]. 
Delivery of CRISPR/Cas9 components to post-mitotic tissues in vivo is commonly 
performed by the injection of viral vectors into the target tissue or via nanoparticles (Figure 





could also induce mutations in the injected tissue [70]. Delivery of CRISPR/Cas9 
components can also be achieved by hydrodynamic injection. This technique involves the 
rapid injection of a large volume of CRISPR/Cas9 solution through a blood vessel, after 
which it will end up in the liver [68, 71]. However, this technique has not been proven to 
be safe for humans. 
 
1.5. CRISPR/Cas9 efficiency and specificity 
CRISPR/Cas9 can efficiently induce indel mutations in its target sequences. When 
combined with a good transfection and selection method, mutation induction by 
CRISPR/Cas9 can reach near 100% efficiency [36, 41]. Lower mutation efficiencies may 
result from lower transfection efficiencies. However, studies by Doench et al. [72, 73] 
suggest that different gRNAs may have different effectiveness depending on the features of 
their sequences. Based on these authors’ recommendations, criteria for effective gRNAs 
include having a balanced GC content, having adenine in the central sequence of the 
gRNA, having guanine and avoiding cytosine at the gRNA sequence position 20 (adjacent 
to the PAM), and having a cytosine and avoiding guanine at gRNA sequence position 16. 
To facilitate the design of effective gRNAs, they also generated an algorithm for predicting 
the on-target efficiency of gRNAs, which is available as a gRNA design tool at 
http://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design, at Benchling 
CRISPR design tools, https://benchling.com/ and at CRISPOR http://crispor.org/. 
Although generating indel mutations is typically very efficient using CRISPR/Cas9 
technology, performing genomic modifications, such as insertions and substitutions, still 
requires enormous improvement to increase the efficiency of these processes. Improved 
HDR efficiency can be achieved by inhibiting the NHEJ pathway, which is expected to 







Figure 1.5 | Various applications of CRISPR/Cas9 genome editing. (A) Cas9 nuclease 
can be modified to become a nickase. (B) Paired nickases using two gRNAs located nearby 
with the correct orientations could be used to generate DSB with less off-targets. (C) 
Genome modification in cells can be achieved by delivery of CRISPR/Cas9 to cells via 
plasmid or viral vectors. (D) CRISPR/Cas9 can be microinjected into fertilised egg to 
generate a mutant animal. (E) CRISPR/Cas9 can be delivered in vivo through viral 
injection. (F) Schematic of a CRISPR/Cas9-based forward genetic screening experiment. 






increased HDR when they inhibited NHEJ factors such as Lig4, DNA-PKcs and Ku using 
chemical inhibitors, such as Scr7, NU7441 and KU-0060648, or by using a siRNA knock-
down approach [74-76]. One study screened 4,000 small molecules and found two 
molecules, L755507 and Brefeldin-A, which could enhance HDR activity [77]. The other 
strategies to increase insertion efficiency are utilising the more efficient NHEJ and MMEJ 
pathways by providing the donor suitable for these repair mechanisms, such as those in the 
HITI and PITCh methods discussed earlier (Figure 1.4) [58-60]. Increased insertion 
efficiency can also be achieved by using modified oligo donors, such as phosphorothioate-
modified oligonucleotides to slow down the process of ssODN degradation inside the cells 
[78], or by using donors containing selection markers to allow for enrichment when they 
are transfected into cultured cells [79]. 
Unfortunately, efficient cleavage mediated by simple RNA-DNA binding of CRISPR/Cas9 
system comes at a cost: unwanted cleavage at non-target sites (off-targets). Fu et al. [80, 
81] observed that CRISPR/Cas9 could target sites with few mismatches to the on-target 
sequences. The mismatch positions also determine the likelihood that a site will be a 
potential off-target, with mismatches at positions distal from the PAM likely to be better 
tolerated by Cas9. They also found that SpCas9 appears to tolerate NAG PAM sequences, 
which should be considered when choosing gRNA sequences with reduced off-target 
activities. To assess the off-target effects of Cas9 cleavage accurately and globally, some 
studies have performed unbiased genome-wide off-target analysis using techniques such as 
IDLV-capture, GUIDE-seq, BLESS, digenome-seq, HTGTS and CIRCLE-seq. Genome-
wide unbiased off-target analysis revealed that off-targets in the CRISPR/Cas9 system 
were more significant than was previously thought. Off-targets could be detected at sites 
with up to six mismatches, at sequences with a 1 bp bulge mismatch, and even at sites with 






Since off-targets can be undesirable in experiments, particularly in experiments for 
therapeutic uses, scientists have developed ways to reduce off-targets and increase 
specificity. One way is to choose unique targets with minimal potential off-targets through 
computational off-target predictions. While choosing 20 bp target sequences that contain 
NGG PAM sequences is an easy task, choosing targets that are not only unique in the 
genome, but also contain many mismatches to avoid mis-binding by CRISPR/Cas9, is 
challenging. Therefore, scientists have developed gRNA design tools that can predict 
potential off-targets by computationally gathering sites with few mismatches to the on-
target sequences. Many software applications have been generated for designing gRNAs, 
including the commonly used tool generated by Feng Zhang’s lab at MIT 
http://crispr.mit.edu/. A complete list of the available CRISPR design tools can be found 
from this link http://goo.gl/R0gANl. One of the newest tools that claims to better predict 
off-targets and incorporate comprehensive scoring of other aspects, such as on-target and 
micro-homology, is CRISPOR at http://crispor.org/ [87]. Although these CRISPR design 
tools help to reduce potential off-targets, they cannot guarantee that gRNAs with good off-
target scores will prevent off-target effects. Genome-wide off-target studies have indicated 
that many of the detectable off-targets were missed by CRISPR design tool predictions, 
and thus off-targets should be determined experimentally in an unbiased way [82]. 
It has been shown that high concentrations of Cas9 and gRNAs create more off-targets. 
Therefore, some studies suggest delivering CRISPR/Cas9 components in RNP or RNA 
form instead of in DNA form because of their short half-lives. When expressing Cas9 and 
gRNAs from the DNA form, off-target effects can be minimised by reducing the amount of 
Cas9 and gRNA expression; for example, by transient transfection of low amounts of 
plasmids (which might also reduce the on-target efficiency), or by controlled expression, 
such as by using a drug inducible strategy or restricting Cas9 expression by using spatially- 





Other studies have suggested gRNA modifications as an alternative way to reduce off-
targets. Keith Joung’s lab showed that truncated gRNAs (17–18 nt instead of 20 nt) 
resulted in reduced off-targets when tested by unbiased genome-wide off-target analysis 
[82, 92]. Another study showed reduced off-targets when adding two G nucleotides to the 
5’ end of gRNA sequences [93]. 
In addition, Cas9 itself has been modified to reduce off-target effects. One of these 
modifications involved altering Cas9 to create a nickase rather than a nuclease. To induce a 
DSB, Cas9 relies on two nuclease domains, HNH and RuvC, which cut the gRNA target 
and non-target strands, respectively (Figure 1.5A). By slight base substitutions to either the 
RuvC (D10A) or HNH domain (H840A), the nuclease activity of these domains can be 
inactivated. Inactivation of one nuclease domain generates Cas9 with nickase function, 
meaning that it cuts only one strand of DNA, which can efficiently be repaired without 
inducing mutations in cellular systems (Figure 1.5A and B). This nickase activity can be 
exploited to induce HDR without a break. However, the efficiency is very low compared to 
nuclease-mediated HDR, although this can be slightly improved by using asymmetric 
ssODN donors [28, 94, 95]. When Cas9 nickase is delivered with two closely spaced 
gRNAs targeting different strands (pairing) (Figure 1.5B), the two nickases will generate 
DSBs, which leads to mutations. Since pairing is compulsory for the dual-nickase to 
induce DSBs while the single-nickase lacks mutagenic outcomes, the paired-nickase 
strategy can dramatically reduce off-targets [28, 83, 93, 95]. 
This pairing strategy can also utilise another modification of Cas9, known as dCa9-Fok1. 
In dCas9-Fok1 technology, both nuclease domains of Cas9 have been inactivated by 
mutations D10A/H840A, thus resulting in catalytically dead Cas9 (dCas9), which cannot 
cleave DNA but still retains RNA-guided DNA binding activity. This dCas9 is then fused 





to induce DSBs when dimerised. Studies have shown that paired-dCas9-Fok1 guided by 
two gRNAs can induce mutations efficiently, while reducing mutagenic effects at off-
target sites [96, 97]. 
Guided by the structure of the Cas9 protein, two groups have engineered SpCas9 to 
improve its specificity, thereby reducing off-target effects. The first group generated Cas9 
with enhanced specificity, eSpCas9, by mutating Cas9 at K848A, K1003A and R1060A in 
the expectation that this would reduce helicase activity by weakening the interaction 
between Cas9 and the non-target DNA strand. The second group attempted to reduce the 
interaction between Cas9 and its target strand by creating Cas9 with high fidelity, SpCas9-
HF1, which harbours mutations N497A, R661A, Q695A and Q926A. Both groups showed 
that their engineered Cas9 could decrease or even eliminate off-targets as measured by 
unbiased genome-wide off-target analyses while maintaining good cleavage activities at 
on-target sites [98, 99]. 
 
1.6. Variations of the CRISPR/Cas system 
The most commonly used CRISPR/Cas system is SpCas9, which natively recognises NGG 
PAM sequences. NGG sequences are abundant in the human genome, occurring on 
average every 8–12 bp, which makes it relatively simple to identify Cas9 target sites [27, 
80]. However, some applications require cleavage at certain positions, such as those 
involving HDR, which is most efficient when the cleavage site located in close proximity 
to the sequence to be modified. This can be a problem if an NGG PAM sequence is not 
available. Therefore, it is necessary to expand the number of editing tools. This can be 
achieved by identifying additional CRISPR endonucleases with different PAM 
specificities. Fortunately, the CRISPR/Cas9 system is found not only in Streptococcus 





that have been characterised include those from Francisella novicida (Fn), Staphylococcus 
aureus (Sa), Streptococcus thermophilus (St) and Neisseria meningitidis (Nm), which all 
recognise different type of PAM sequences (apart from Fn) and thus can broaden the 
number of targetable regions in the genome (Figure 1.6) [3, 4, 69]. Furthermore, some 
have smaller amino acid size, meaning that delivery using versatile AAV vectors with 
limited packaging capacity becomes possible [69]. 
A recent development in the genome engineering field is the discovery of a novel RNA-
guided endonuclease, Cpf1, which is distinct from Cas9. The Cpf1 from Acidaminococcus 
sp. (AsCpf1) and from Lachnospiraceae bacterium (LbCpf1) have been shown to be 
capable of inducing mutations in mammalian genomes, with comparable efficiency to 
SpCas9 [100-102]. There are several interesting differences between the Cpf1 and Cas9 
systems. The PAM requirement for Cpf1 is TTTN and is located at the 5’ end of target 
sequences, in contrast to Cas9 system, where the PAM is located at the 3’ end (Figure 1.6). 
Unlike the native CRISPR/Cas9 system, which is guided by two short RNA components 
(crRNA and tracrRNA), native Cpf1 only uses one short crRNA (~42 nt) without the 
requirement for a tracrRNA. While Cas9 cleaves DNA at a site near the PAM, generating 
blunt-ended products, Cpf1 cleaves sequences 18–23 bases away from the PAM sequence 
in a staggered conformation, generating 5’ overhang products (Figure 1.6). These 
characteristics have numerous advantages for genome editing. The unique PAM 
requirement may be able to target thymidine-rich genomic regions, thus expanding the 
targetable sites. The short gRNA required by Cpf1 makes it less expensive when 
commercially purchased. Cpf1 can also cleave its own pre-crRNA to generate mature 
crRNAs, therefore allowing multiplex expression of the gRNAs from a single promoter 
[103, 104]. Since the cutting sites of Cpf1 are further away from the PAM sequences and 
are located outside the target sequence (if a 20 nt gRNA is used), it is thought that 





sequence and make it prone to Cpf1 re-targeting. This means that the process of re-
cleavage and repair takes more rounds compared to Cas9 cleavage. Multiple rounds of re-
cleavage by Cpf1 due to NHEJ failure to modify the target sequence theoretically increases 
the chance of HDR repair when a DNA donor is provided, thus improving knock-in (KI) 
efficiency [100, 105]. Furthermore, Cpf1 has been shown to generate less off-targets 
compared to Cas9 [106, 107]. 
Besides screening for other natural RNA-guided endonuclease systems that cut different 
PAM sequences to broaden the range of targets, scientists have also engineered Cas9 so it 
can recognise different or relaxed PAM sequences. It was discovered that SpCas9 
harbouring the mutations D1335V/R1335Q/T1337R (SpCas9-VQR), 
D1135E/R1335Q/T1337R (SpCas9-EQR) and D1135V/G1218R/R1335E /T1337R 
(SpCas9-VRER) could recognise NGA, NGAG and NGCG PAMs, respectively [98]. 
Engineering the FnCas9 by mutations E1369R/E1449H/R1556A (FnCas9-RAH) relaxes 
the PAM recognition from NGG to YG despite a low targeting efficiency when tested by 
mouse zygote injections [108]. Relaxed PAM recognition was also achieved by 
engineering SaCas9 with mutations E782K/N968K/R1015H (SaCas9-KKH), which led to 
the recognition of the more flexible NNNRRT PAM compared to the original PAM 
NNGRRT (Figure 1.6) [109]. 
Recently a novel system, NgAgo from Natronobacterium gregoryi, has sparked interest in 
the genome editing field since it was reported to induce DSBs by an endonuclease guided 
by short oligos without a requirement for PAM sequences [110]. However, this new 
system cannot be replicated by other scientists [111, 112], which led to the original paper 







Figure 1.6 | CRISPR systems. The commonly used CRISPR system is from SpCas9, 
which recognises NGG PAM sequences and generates blunt-ended DSB. Alternative 
CRISPR systems from different species can be utilised for genome editing purposes and 
recognise different PAM sequences.  Note that CRISPR/Cpf1 generates staggered breaks 
away from the PAM. Cas9 can also be engineered to recognise different or relaxed PAM 






1.7. Catalytically dead Cas9 for non-cleaving applications 
As mentioned above, the nuclease domains of SpCas9 (RuvC and HNH) can be inactivated 
without abrogating its binding ability, producing catalytically dead Cas9 (dCas9) [26]. By 
fusing dCas9 with other proteins, scientists are able to direct proteins of interest to specific 
loci through gRNA-dCas9 binding activity. dCas9 has been fused with transactivator 
domains, such as VP64 and P65, for targeted gene activation, called CRISPR activation 
(CRISPRa) [28, 113-116], or with repressor domains, such as KRAB, to repress 
transcription of target genes, known as CRISPR interference (CRISPRi) [117, 118]. 
Targeted epigenetic changes of chromatin can be achieved by fusion of dCas9 with 
methyltransferase (DNMT3A), DNA demethylase (Tet1) or acetyltransferase (p300) [119-
124]. Recent studies fused dCas9 with the rat cytidine deaminase rat APOBEC1 to 
performing genomic nucleotide substitution without DSB and HDR (cytidine deaminase 
catalyses C  T or G  A exchange. dCas9-APOBEC1 was shown to be able to produce 
these point mutations in a targeted manner. The base editing activity was improved by 
using a fusion of APOBEC1 with Cas9-nickase (H840A) and the uracil glycosylase 
inhibitor (Base Editor 3, or BE3). While the uracil glycosylase inhibitor inhibits the 
process of base excision repair (BER) that removes uracil from the DNA, the use of Cas9-
nickase can stimulate mismatch repair, which will assist nucleotide replacement [125, 
126]. Furthermore, dCas9 can also be fused to fluorophores to enable the visualisation of 
DNA in a sequence-specific manner. More interestingly, this sequence-specific labelling 
can be performed in live cells. Ma et al. have developed the CRISPRainbow technique, 
which can visualise six different loci simultaneously, greatly improving chromosomal 






1.8. Biomedical applications of CRISPR/Cas9 genome editing 
Since CRISPR/Cas9 was shown to be useful for genetically manipulating mammalian cells 
[27, 129], researchers have used this technology to alter the genomic sequences of their 
species of interest in many ways. Researchers mainly use CRISPR/Cas9 to knock out 
genes in cells to study gene function. Certain modifications designed to mimic mutations 
found in human diseases can also be created using the CRISPR/Cas9 system to model and 
study human diseases. The insertion of fluorescent markers or a HA/Flag tag to label genes 
of interest is useful to track their expression or for immunoprecipitation purposes. In 
addition, many researchers aim to develop molecular therapies for a range of diseases. 
Therefore, many experiments have been conducted to show that CRISPR/Cas9 is able to 
repair mutations in primary or stem cells, including induced pluripotent stem cells (iPScs), 
which possess the ability to differentiate into many kinds of tissues. The expectation of 
these kinds of experiments is that the edited cells can be used to replace faulty cells [1, 2, 
4, 6-8, 130]. 
One important application of CRISPR/Cas9 genome editing is for the generation of 
genetically modified animal models, particularly mice, to study genetic function or model 
diseases in vivo. Unlike the generation of mutant mice using conventional gene targeting in 
ES cells, which may take years, the generation of genetically modified mice using 
CRISPR/Cas9 can be accomplished quickly and relatively easily (Figure 1.7). This 
involves the microinjection of CRISPR/Cas9 components into fertilised mouse zygotes to 
edit the genome before transplanting the zygotes to pseudo-pregnant females to generate 
founder animals. Generating small indels that may constitute frameshift alleles can reach 
nearly 100% efficiency. Targeting multiple genes for simultaneous knockout is also 







Figure 1.7 | Comparison of genetically modified mouse generation using 
CRISPR/Cas9 technology (left) and an approach using gene targeting in mouse ES 
cells (right). CRISPR/Cas9 injection to mouse zygotes can efficiently induce mutations 






Making small changes, such as point mutations or inserting an epitope tag using a ssODN 
donor is less efficient but readily achievable. However, generating large insertions with a 
plasmid donor via HR can be problematic and is difficult to achieve in some cases. 
Generating conditional KO mice with Cre-Lox system, an approach suitable for targeting 
genes important in embryonic development, is also still inefficient using CRISPR/Cas9 
technique. This limitation forces some researchers to go back to the ES cell gene targeting 
approach when generating conditional KO mice or mice containing large insertions. 
Despite these current limitations, the simplicity offered by the CRISPR/Cas9 system is 
undoubtly a breakthrough in the mouse transgenesis field [9, 35, 51, 54]. Further 
optimisation will likely lead to increased efficiency of knock-in approaches. 
CRISPR/Cas9 genome editing is envisioned to be used for ex vivo or in vivo disease 
therapies, particularly for diseases caused by mutations (Figure 1.8). Studies of the 
potential of the CRISPR/Cas9 system for therapeutic use have shown promising results. 
Correction of mutations by CRISPR/Cas9 can be performed in zygotes to generate a 
healthy individual. This has been tested in mice by microinjection of zygotes to treat 
diseases. For example, the CRISPR/Cas9 components were injected into a zygote 
heterozygous for a dominant-negative point mutation in the CRYGC gene, which causes 
cataracts. By targeting Cas9-mediated DSB to the mutant allele only, the defective point 
mutation was repaired by copying the correct allele (inter-homologue repair), resulting in 
cataract-free mice [55]. This inter-homologue repair mechanism is also utilised to correct 
heterozygous mutation in human preimplantation embryos using CRISPR/Cas9 platform 
[32]. In the study, scientists targeted MYBPC3 gene in which the heterozygous mutation in 
human can lead to hypertrophic cardiomyopathy. By injecting CRISPR/Cas9 RNP to the 
human fertilised eggs resulting from in vitro fertilisation between MYBPC3WT/∆GAGT male 
and MYBPC3WT/WT female, they were able to fix the mutant alleles efficiently. Despite 





diagnosis (PGD), their approach could potentially be useful to improve the number of 
healthy embryos for more successful pregnancy rate [32]. 
Zygote injection of CRISPR/Cas9 and donor template has been shown to correct the point 
mutation that causes Duchenne muscular dystrophy (DMD) in a mouse model of DMD 
[131]. Post-natal treatment for this mouse model was achieved by AAV-mediated delivery 
of SaCas9 or SpCas9 and gRNAs to skeletal and cardiac muscle cells to delete the mutated 
exon in an exon skipping strategy. This strategy successfully led to expression of 
dystrophin and improved muscle function [132-134]. 
Defective point mutations in the ornithine transcarbamylase (OTC) gene, which cause 
metabolic disease, were shown to be corrected in the livers of newborn mice by 
intravenously infusing AAVs expressing Cas9, gRNA and a donor DNA. Mutation 
corrections occurred in 10% of hepatocytes, which resulted in increased survival when the 
mice were challenged with high-protein diet [135]. CRISPR/Cas9-mediated mutation 
corrections have also been performed in mice with the liver disease hereditary 
tyrosinaemia type I (HTI), which results from a point mutation in the Fah gene [71, 136]. 
By systemic delivery of Cas9 mRNA coated in lipid nanoparticles and sgRNA/HDR 







Figure 1.8 | Schematic of in vivo and ex vivo CRISPR/Cas9 therapy. CRISPR/Cas9 
components can be injected as a viral vector or via nanoparticles to reach targeting tissues 
for in vivo therapeutic applications. Cells from patients can also be harvested and 
genetically modified/repaired in vitro before transplanted back into the patient. Cells, such 
as fibroblasts, from patients can also be induced to become iPSCs, then genetically 
modified in vitro. Modified iPSCs can then be differentiated to become the desired type of 






CRISPR/Cas9 has been tested for the correction of a rat model of retinitis pigmentosa (a 
visual degeneration disease), where mice a carry a homozygous 1.9-kb deletion from intron 
1 to exon 2 in the Mertk gene. Retinal injection of AAVs carrying CRISPR/Cas9 and donor 
DNA resulted in correction of the mutation in the eyes, expression of the functional Mertk 
gene and improved visual responses [60]. AAV delivery of SpCas9 or SaCas9 to mouse 
liver, targeting the PCSK9 gene for loss of function, successfully lowered the cholesterol 
levels in mutant mice, which could be useful to protect against cardiovascular disease [69, 
138]. In another model, electroporation of RNP and a DNA donor into haematopoietic 
stem/progenitor cells (HSPCs) could correct the point mutation in the HBB gene that 
causes sickle cell disease [139, 140]. The edited HSPCs could be maintained for 16 weeks 
when engrafted into immunocompromised mice [139]. 
CRISPR/Cas9 genome editing could be used to knock out the CCR5 gene in T cells and 
thus confer resistance to HIV infection [141-143]. This strategy has been used with ZFN in 
a clinical trial, with promising results. CD4+ T cells from patients with HIV were edited ex 
vivo by ZFN to knock out the CCR5 gene, and the cells were transplanted back into the 
patients [144]. Eliminating the HIV genome via CRISPR/Cas9 cuts has also been proposed 
as a strategy for HIV therapy [145-147]. Cancer treatment with CRISPR/Cas9 genome 
editing could be achieved by cancer immunotherapy; for example, by knocking out the 
PD1 gene in the patient’s T cells ex vivo, followed by engraftment of the edited cells in the 
patient. These PD1-KO T cells are expected to robustly kill the cancer cells [148]. Killing 
cancer cells could also be realised by CRISPR/Cas9-mediated insertion of genes that cause 
apoptosis. A recent study used the paired-nickase strategy to insert the HSV1-tk gene into a 
cancer-specific genomic locus by adenovirus delivery of the CRISPR/Cas9-nickase 
components and the HSV1-tk construct. Treatment with ganciclovir forces the cancer cells 
containing the HSV1-tk cassettes to suicide, thus decreasing tumour size, as shown in 





harmful bacteria in vivo by delivering bacteriophage carrying CRISPR/Cas9 that uniquely 
cleave the bacterial genome or plasmids in certain bacteria to cause lethality or antibiotic 
re-sensitisation [150-152]. 
The ability of CRISPR/Cas9 technology to easily knock out genes by frameshifting the 
open reading frame (ORF) via indel mutations has been used for genome-wide forward 
genetic screening to identify genes that play a role in producing a phenotype of interest. 
Lentiviral vectors carrying Cas9 and gRNA libraries targeting all genes, or clusters of 
genes, for loss of function are pooled and cells are infected in the expectation that only one 
gRNA is present in each cell to knock out a certain gene. The pooled cells are then 
subjected to treatment with a certain phenotypic consequence; for example, resistance to 
certain drugs. Cells that display the phenotype of interest are checked by sequencing to 
determine which gRNAs are enriched (or which genes have been knocked out) to give rise 
to the phenotype (Figure 1.5F) [153-157]. Genome-wide screening using dual gRNA 
libraries could be conducted to study the impact of deletion of regulatory elements or 
lncRNA, which requires larger deletions rather than small indels, or to uncover the 
interaction between two genes that give rise to a certain phenotype via its ability to 
simultaneously knock out two different genes [158-160]. 
CRISPR/Cas9 can be harnessed to create a gene drive system. Using gene drive 
(sometimes called the ‘mutagenic chain reaction’ or MCR), desired genetic modifications 
can be rapidly spread through a population by sexual reproduction. Normally, in biallelic 
organisms, a parent will transmit one copy of its genes to the offspring, while another copy 
comes from the other parent. Crossing a WT parent with a parent carrying one copy of a 
modified gene will result in 50% of the offspring being heterozygous for the modified 
gene. Further crossing of the heterozygotes with WT will again produce only 





drive system, crossing of a WT parent with a parent with one copy of a modified gene will 
produce homozygotes in all offspring, instead of heterozygotes, breaking the Mendelian 
law of inheritance. Further crossing of the homozygotes with the WT will always produce 
100% homozygous offspring, thus rapidly spreading the modified genes through the 
population (Figure 1.9). This is possible because the CRISPR/Cas9 gene drive system will 
generate DSB in the WT allele during conception or specifically in the germ cell lineage 
and these breaks will be mostly repaired by the HR mechanism, which uses the sister 
chromatid containing the modified allele and the gene drive cassette as the HR template, 
thus copying the modified genes and the gene drive cassette to the WT allele (Figure 1.9). 
This gene drive system has been tested in flies, yeast and mosquitoes, and was able to 
spread the gene of interest in the population with an efficiency of almost 100% [161]. This 
is opens the possibility of controlling populations that are harmful, such as mosquitoes that 
cause malaria and dengue, by spreading genes/cassettes that cause gender imbalance or 
sterility thus reducing their populations [162]. Another use for the gene drive system may 









Figure 1.9 | Schematic of gene drive (mutagenic chain reaction). Normal Mendelian 
inheritance (left figure) cannot spread genetic sequences of interest (red mosquitoes) 
rapidly. While using CRISPR/Cas9 gene drive system (right figure), the WT alleles will 
always be forced to convert to the intended genetic modification and thus modified genes 







1.9. Project rationale 
CRISPR/Cas9 genome editing technology has produced significant advances in life science 
research and holds great potential for disease modelling and therapeutics. The development 
of CRISPR/Cas9 technology has been very rapid. However, there is still room for 
improvements. The study reported in this thesis aims to improve the usefulness of 
CRISPR/Cas9 technology. The specific aims include: 
1. Applying CRISPR/Cas9 technology for gene swapping in mice to study functional 
redundancy between two genes. 
2. Developing strategies for deleting an entire chromosome using the CRISPR/Cas9 
system. 
3. Developing versatile plasmid vectors that help researchers to perform 
CRISPR/Cas9 genome editing. 













Chapter 2:  
Functional equivalence of the SOX2 
and SOX3 transcription factors in 








One of the major advantages of CRISPR/Cas9 technology lies in its ability to generate 
genetically modified mice quickly and easily. In this chapter, this property is exploited to 
create a unique mouse model to study the functional redundancy between two genes is 
described. The study presented in this chapter has been published in Genetics as a paper 
entitled ‘Functional equivalence of the SOX2 and SOX3 transcription factors in the 
developing mouse brain and testes’. 
This paper addresses a long-standing question in the developmental biology field: whether 
the SOXB1 transcription factor family members (SOX1, SOX2 and SOX3) function 
redundantly and can compensate for the loss of another member, leading to phenotypic 
rescue in individual KO mice. Although they are structurally and functionally similar, until 
the current study there was no strong and direct evidence to claim that they were 
functionally equivalent. The most robust and physiological approach to study functional 
redundancy between two genes is by performing gene replacement in vivo. Therefore, we 
attempted to generate a mouse model where the Sox3 ORF was replaced with that of Sox2. 
These mice, called Sox3Sox2KI, lack Sox3, but express extra Sox2 in the same spatio-
temporal pattern as that of Sox3. If the ectopic Sox2 can rescue the Sox3-null phenotype, 
this means that Sox2 and Sox3 function redundantly. 
Previous efforts to generate this mouse model using gene targeting in ES cells failed due to 
unknown reasons. This is not unusual, as the generation of mouse models by this 
conventional technique requires many steps that are prone to failure. CRISPR/Cas9 
technology was therefore chosen for generating the Sox3Sox2KI mice. Despite a low KI 
frequency, Sox3Sox2KI mice were successfully generated and used to answer the research 





We showed that Sox3-null phenotypes, such as testis defects and pituitary dysmorphology, 
are largely rescued in Sox3Sox2KI mice. Microarray analyses comparing genome-wide 
expression in Sox3KO vs WT testes revealed the presence of widespread genetic 
dysregulation in Sox3-null testes. These Sox3KO genetic alterations are normalised in 
Sox3Sox2KI testes, establishing that the Sox3-null phenotypic rescue by Sox2 results from its 
ability to rescue at the molecular level. Overall, CRISPR/Cas9 technology has facilitated 
this study, which provides robust evidence of functional equivalence between the SOX2 
































































































































Chapter 3:  
Targeted deletion of an 








Genome editing has been used to model genetic diseases and holds great promise for their 
treatment. This may be applicable for monogenic diseases, but remains a challenge for 
diseases caused by supernumerary chromosomes (aneuploidy), such as Down syndrome, as 
this requires modification of an entire chromosome, which has not been shown to be 
possible with existing genome editing technologies, including CRISPR/Cas9. Therefore, 
this project aimed to develop strategies to facilitate genome editing at the chromosomal 
level. 
It was hypothesised that deletion of an entire chromosome could be achieved by deleting 
its centromere, or by bombardment of the chromosome arm with multiple cuts (shredding). 
These hypotheses were tested in vitro in mouse ES cells and in vivo by mouse zygote 
injection, by attempting to delete the Y chromosome (~90 MB in size) as loss of this 
chromosome does not affect cell/mouse growth and viability. To efficiently delete the 
centromere, gRNAs that target repetitive sequences that cut the centromere 140X and 41X 
were employed. Surprisingly, efficient Y chromosome depletion of up to 85%, as 
measured by qPCR analyses, was observed. Two cuts flanking the Y centromere for 
intervening deletion could still efficiently delete the Y chromosome with ~40% efficiency. 
To test whether shredding the Y arm could result in Y loss, gRNAs that target repetitive 
sequences in the Y long arm were employed. These gRNAs enabled the Y long arm to be 
cut 298X, 116X, 45X, 8X and 2X. All gRNAs, apart from gRNA 2X, could obviously 
induce Y deletion with an efficiency correlating with the number of cuts, ranging from 27–
82%, whereas gRNA 298X was the most efficient. This highly efficient Y loss was 
confirmed by Y painting FISH analysis. 
This strategy was then tested in vivo by microinjection of gRNA centromere 41X and Cas9 





gonadal phenotypes and the genotypes of the mice were assessed, and females with an XO 
genotype were detected, indicating the successful application of this strategy in vivo. 
Collectively, the study described in this chapter has established strategies to delete an 
entire chromosome using CRISPR/Cas9 genome editing that should be applicable to other 
chromosomes for modelling and therapeutic intervention in aneuploidy diseases. This 
study has been published in Molecular Therapy as a paper entitled ‘Targeted deletion of an 

















































Figure S1 Gonadal phenotypes of E15.5 mouse embryos from CRISPR/Cas9 zygote injection. 








Figure S2 Assessment of X chromosome copy number by Sox3 qPCR in female mice injected with 
autosomal gRNAs. Sixteen phenotypically female founder mice generated from injection of autosomal 
gRNAs targeting Ngn3, Foxp4 and Fzd3 genes had two copies of the X chromosome. These data indicate that 
spontaneous loss of the X chromosome does not occur in zygotes injected with CRISPR/Cas9 reagents. Data 









Figure S3 Assessment of Y chromosome dosage in males generated from gRNA centro 41X zygote 
injection. (A) qPCR analysis of Uba1y and Sry (which are located on Y short arm) revealed males with 
reduced Y dosage (asterisks) suggesting mosaic XY-XO. (B) Confirmation of the mosaicism by qPCR of 








Table S1 | List of gonadal phenotypes and genotypes of all mice generated from gRNA centro 41X injection 
Identifier  Gonadal phenotype Genotype  Additional info 
#1 Male XY  
#2 Male XY  
#3 Male XY, XO Mosaic, with more than 70% XY cells 
#4 Female  XO  
#5 Female  XX  
#6 Female  XX  
#7 Female  XX  
#8 Female  XX  
#9 Male XY  
#10 Male XY, XO Mosaic, with more than 70% XY cells 
#11 Male XY, XO Mosaic, with more than 70% XY cells 
#12 Female  XX  
#13 Female  XX  
#14 Male XY  
#15 Male XY  
#16 Female  XX  
#17 Female  XX  
#18 Female  XX  
#19 Female  XO, XYshort_arm Mosaic, half XO, half contain truncated Y 
short arm 
#20 Female  XO, XYshort_arm Mosaic, half XO, half contain truncated Y 
short arm 
#21 Female  XO  
#22 Female  XO, XYshort_arm Mosaic, half XO, half contain truncated Y 
short arm 
#23 Female  XX  
#24 Male XY  
#26 Male XY  
#27 Male XY  
#28 Female  XX  
 
 
Table S2 | On-targets and potential off-targets all the gRNAs used in this study (provided in excel file that 
can be downloaded from the publication source) 
 
Table S3 | The two-way ANOVA statistical analysis of Uba1Y and Erdr1 qPCR related to Figure 1B 












Materials and Methods 
gRNA screening and plasmid construction. sgRNAs were identified by manual screening of Y 
chromosome sequences using the CCTop gRNA design tool http://crispr.cos.uni-heidelberg.de/ provided by 
Stemmer et al. (2015). This tool was also used to predict the off-target potentials containing PAM sequences 
NGG and NAG (Supplementary information, Table S2). PX459.V2.0 (pSpCas9(BB)-2A-Puro, Addgene 
#62988) plasmid was used for Cas9 and sgRNA expression. PX459.V2.0 containing sgRNA was prepared as 
previously described by Ran et al. (2013). For dual gRNA centro 2X and long arm 2X, an additional U6-
sgRNA cassette was added to the NotI site to allow simultaneous expression of two different gRNAs from 
single plasmid. Plasmid preparations were performed using PureLink® HiPure Plasmid Midiprep Kit (Life 
Technologies). 
Cell culture and transfection. R1 mouse embryonic stem cells were cultured in 15% FCS/DMEM 
supplemented with 2 mM Glutamax (Gibco), 100 µM non-essential amino acid (Gibco), 100 µM 2-
mercaptoethanol (Sigma), 3 µM CHIR99021 (Sigma) 1 µM PD0325901 (Sigma) and LIF (generated in-
house). One million of ES cells were nucleofected with 3 µg of plasmid DNA using the Neon™ Transfection 
System 100 µL Kit (Life technologies) at 1400 V, 10 ms and 3 pulses according to the manufacturer’s 
protocol. 24 hr after transfection, selection was conducted by adding puromycin (2 µg/ml) to the media for 
the next 48 hr. Surviving cells were cultured for 4-7 days without selection before harvesting. 
DNA extraction and qPCR. Genomic DNA was extracted from 1-2 million ES cells or tail tissue using 
High Pure PCR Template Preparation Kit (Roche) according to the manufacturer’s instructions. qPCRs were 
performed using Fast SYBR Green Master Mix (Applied Biosystems) on an Applied Biosystems 7500 
StepOnePlus machine. Sox1 qPCR was used as internal reference control to normalize qPCR value in all 
qPCR analyses. 
FISH analysis. Cells were cultured in media containing 0.1 µg colcemid (Roche) for 1-2 hours, harvested 
and incubated in 0.075 M KCl hypotonic solution for 20 minutes. The cells were then fixed using methanol-
acetic acid (3:1) solution, dropped onto slides and dried.  FISH staining was performed using Mouse 
IDetect™ Chromosome Y Paint Probe (Empire Genomics) according to the manufacturer’s instructions. Y 
signals were counted from both metaphase and interphase spreads. 
Mouse zygote injection. All the experiments involving animal use have been approved by the University of 
Adelaide Animal Ethics Committee. Cas9 mRNA was produced by in vitro transcription of XhoI-linearized 
pCMV/T7-hCas9 (Toolgen) using mMESSAGE mMACHINE® T7 ULTRA Transcription Kit (Ambion). 
sgRNA centro 41X was generated according to a previously described protocol.[35] In brief, PCR was 
performed using a T7 containing forward primer 5’-
TTAATACGACTCACTATAGAGGAGTTAATATAAAAAACA-3’ and a reverse primer 5’- 
AAAAGCACCGACTCGGTGCC-3’ and the PX459.V2 centro 41X plasmid template. The product was 
purified by QIAquick PCR Purification Kit (Qiagen) and used as a template for in vitro transcription using 
the HiScribe™ T7 Quick High Yield RNA Synthesis Kit (NEB). RNA purification was conducted using 
RNeasy Mini Kit (Qiagen). Cas9 mRNA (200 ng/µl) and sgRNA centro 41X (100 ng/µl) were injected to the 
cytoplasm of C57BL/6N zygotes using a Femtojet microinjector. The survival rate of injected zygotes was 
89.4% (93/104). 57 zygotes were transferred into 3 pseudo pregnant females (19/recipient). 27 embryos with 
normal appearance were harvested at E15.5 for gonadal assessment and tissue collection. 
List of gRNA sequences used 
Name  gRNA sequences 5’-3’ Position in Y 




Centro 41X GGAGTTAATATAAAAAACA 4.065.169 to 4.159.436 
Centro 140X GAAGAATTACAATGAAAAATA 4.065.349 to 4.161.710 




Long arm 8X GTTCTATGTCAATTTAGGTGG 4.313.453 to 17.275.105 
Long arm 45X GACTGGGTTCTCCTAATCCTT 4.417.594 to 90.167.758 
Long arm 116X GTGGAATTGTGATCTAGATA 5.726.265 to 88.887.822 
Long arm 298X GGCAAAGCACTTCTGCACC 4.596.490 to 90.662.856 
Neo GGCAGCGCGGCTATCGTGGC None in mouse 














Chapter 4:  
Versatile single-step-
assembly CRISPR/Cas9 
vectors for dual gRNA 







The availability of vast array of CRISPR/Cas9 plasmid vectors via repositories such as 
Addgene has been invaluable for researchers who are interested in genome editing. Popular 
CRISPR/Cas9 constructs include vectors from Zhang laboratory at the Broad Institute, 
such as the Cas9 nuclease plasmids pX330, pX458 and pX459.V2 and the Cas9 nickase 
plasmids pX335, pX461 and pX462. These vectors are very user-friendly as they allow 
expression of all CRISPR/Cas9 components (Cas9 and a single gRNA), including selection 
markers (pX458 and pX461 contain a GFP cassette; pX459.V2.0 and pX462.V2.0 contain 
a puromycin resistance cassette) from a single plasmid (all-in-one). Moreover, these 
vectors contain a ‘golden gate’ cloning site at the gRNA site, rendering these vectors easily 
customisable for facile generation of gRNAs of interest by a one-step digestion ligation 
protocol (see http://www.genome-engineering.org/crispr/ for more detail). 
However, some applications require simultaneous expression of two gRNAs, such as 
inducing DSBs using a paired-nickase strategy, generating large deletions or generating 
double KO lines, and there are no vectors available for the simple generation of all-in-one 
plasmids expressing dual gRNAs. Existing multiplex CRISPR/Cas9 vectors require 
multiple cloning or PCR steps to generate all-in-one vectors expressing dual gRNAs. 
This chapter describes the design and construction of versatile CRISPR/Cas9 plasmid 
vectors that allow a one-step cloning reaction for the generation of all-in-one vectors 
expressing dual gRNAs. The previously mentioned CRISPR vectors from Zhang 
laboratory were modified by adding an extra gRNA expression cassette with slight 
sequence modifications at the golden gate cloning site. These modified vectors were 
named pDG330, pDG458, pDG459, pDG335, pDG461 and pDG462, based on the name of 
the original vectors (DG stands for dual gRNAs). Generation of all-in-one vectors 





protocol. The ability of these vectors to perform tasks requiring dual gRNA expression, 
such generating mutations at two different sites, generating intervening large deletions and 
inducing DSBs using the paired-nickase strategy was tested, and all could be accomplished 
efficiently using these dual gRNA vectors. This study is presented as a manuscript that will 
be submitted to a scientific journal. Finally, these vectors will be made available to the 
scientific community through Addgene to help researchers performing experiments 
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Abstract 
CRISPR/Cas9 technology enables efficient, rapid and cost-effective targeted genomic 
modification in a wide variety of cellular contexts including cultured cells. Some 
applications such as generation of double knock-outs, large deletions and paired-nickase 
cleavage require simultaneous expression of two gRNAs. Although single plasmids that 
enable multiplex expression of gRNAs have been developed, these require multiple rounds 
of cloning and/or PCR for generation of the desired construct. Here, we describe a series of 
vectors that enable generation of customized dual-gRNA expression constructs via an easy 
one-step golden gate cloning reaction using two annealed oligonucleotide inserts with 
different overhangs.  Through nucleofection of mouse embryonic stem cells, we 
demonstrate highly efficient cleavage of the target loci using the dual-guide plasmids, 
which are available as Cas9-nuclease or Cas9-nickase expression constructs, with or 
without selection markers. These vectors are a valuable addition to the CRISPR/Cas9 
toolbox and will be made available to all interested researchers via the Addgene plasmid 






CRISPR/Cas9 technology is a powerful genome editing tool that has become widely used 
by researchers to generate targeted genetic modifications in many contexts including 
cultured cell lines and zygotes.  CRISPR/Cas9 offers several advantages over preexisting 
genome editing technologies including ease of use, relatively low cost and high activity 
(Barrangou and Doudna, 2016; Hsu et al., 2014; Komor et al., 2017; Mali et al., 2013b; 
Sander and Joung, 2014). The CRIPSR/Cas9 platform comprises two components; Cas9, 
which functions as a programmable endonuclease that generates a blunt-ended double-
stranded break (DSB) and a ~100 nt guide RNA (gRNA), in which the ~20 nt at the 5’ end 
directs Cas9 to the target site via RNA:DNA complementary base pairing (Cong et al., 
2013; Jinek et al., 2012; Mali et al., 2013c).  Generation of a targeted DSB can be achieved 
by delivery of Cas9 and gRNA components in plasmid, RNA or ribonucleoprotein (RNP) 
forms. For some applications, such as cultured cells, plasmids are generally preferred due 
to their ease of generation and stability.  Commonly used plasmids for expression of Cas9 
or Cas9-nickase (D10A) and single gRNA are available from the Zhang laboratory and can 
be obtained through the Addgene plasmid repository. These plasmids contain both gRNA 
and Cas9 expression cassettes in a single plasmid with optional selection markers such as 
puromycin or GFP to facilitate screening. Importantly, generation of a unique customized 
gRNA of interest can be performed easily as the gRNA cloning site contains BbsI 
restriction sites, allowing a one-step golden gate cloning approach for insertion of a pair of 
annealed oligonucleotides containing the specific ~20 bp guide sequence (Cong et al., 
2013; Ran et al., 2013b). 
To simultaneously target a pair of genomic regions, expression of two gRNAs is required.  
While this can be achieved by co-transfection of two plasmids, this process can be 





should be expressed from a single plasmid. Single plasmids expressing multiple gRNAs 
have been developed, however generation of the desired constructs using those existing 
plasmids require multiple cloning and/or PCR steps. Here we modify commonly-used 
vectors from the Zhang laboratory so that each plasmid can express two gRNAs and can be 
generated via a simple one-step cloning method.  We show that these plasmids, termed 
dual-gRNA plasmids, provide an efficient tool for experiments requiring simultaneous 
expression of two gRNAs such as multiplexed knock-out of two genes, generation of large 
deletions and generation of indels using Cas9-nickase. These vectors are a valuable 




Generation of vectors 
To generate plasmids that permit simultaneous expression of two gRNAs, we inserted an 
additional hU6-gRNA expression cassette into the available CRISPR plasmids from the 
Zhang laboratory. The second cassette was positioned in the opposite orientation to the 
original hU6-gRNA expression cassette to reduce the possibility of recombination (Fig. 
1A). The additional cassette also contains a BbsI golden gate site at the guide insertion site 
as per the original cassette. However, unlike the original BbsI site which generates GTTT 
and GGTG overhangs, the new site generates CGGT and TTTA overhangs (Fig. 1B) 
allowing simultaneous targeted insertion of two annealed oligonucleotides with different 
complementary overhangs in a one-step digestion-ligation reaction (Fig. 1C; see below). 
We added the extra gRNA cassette to the following Cas9 nuclease vectors: pX330 (no 





marker), and to the following Cas9-nickase vectors: pX335 (no selection marker), pX461 
(GFP selection marker) and pX462.V2.0 (puromycin selection marker). Those vectors 
were named pDG330, pDG458, pDG459, pDG335, pDG461 and pDG462, respectively. 
 
Efficient generation of custom dual-gRNA vector using a one-step cloning protocol   
Having generated the dual-gRNA vectors, we next tested whether we could simultaneously 
insert two annealed oligonucleotide duplexes in a one-step cloning process. We designed 
two gRNA oligonucleotide inserts targeting the mouse Sox1 and Sox3 genes. These inserts 
carried BspMI and SacI restriction sites at the original and second hU6-gRNA sites, 
respectively. Annealed oligonucleotide duplex pairs and pDG459 vector were subjected to 
a one-step digestion-ligation cycling protocol followed by bacterial transformation (Fig. 
1C). All 12 colonies analyzed contained vectors with correct assembly based on their 
RFLP pattern (Fig. 1D). This demonstrates that our dual-gRNA vector design combined 
with the one-step cloning protocol can allow easy and efficient generation of 
CRISPR/Cas9 vectors with dual-gRNA expression cassettes. 
 
Efficient generation of DSB at two sites using vectors expressing Cas9 nuclease and 
dual-gRNAs 
We next tested whether the dual-gRNA Cas9-nuclease vectors could efficiently induce 
indels or deletions through simultaneous digestion at two target sites. Four different 
pDG459 derivatives were initially generated; the first targeted Sox1 site A and Sox3 site A 
(pDG459 Sox1A/Sox3A), the second targeted Sox1 site B and Sox3 site B (pDG459 
Sox1B/Sox3B), the third targeted Sox1 site A and Sox1 site B (pDG459 Sox1A/Sox1B) 





Sox3A/Sox3B) which are separated by 47 bp (Fig. 2A). All target sequences contained 
restriction sites and hence indel generation at each site could be assayed by RFLP analyses. 
In addition, efficient digestion by pDG459 Sox1A/Sox1B or pDG459 Sox3A/Sox3B 
gRNAs should cause a deletion of ~50 bp which can be readily detected by PCR. Each of 
the four constructs were separately transfected to the mouse ES cells followed by 
puromycin selection to ensure only transfectants were harvested. Sox1 and Sox3 PCRs 
were performed on Sox1A/Sox3A-treated samples followed by a BfuAI (isoschizomer of 
BspMI) and SacI RFLP assay to assess indel generation at Sox1A and Sox3A sites, 
respectively. Both RFLP analyses indicated that pDG459 Sox1A/Sox3A plasmid induced 
mutations with ~100% efficiency at both Sox1A and Sox3A sites (Fig. 2B and Fig. S1A). 
Highly efficient mutagenesis of the Sox1B and Sox3B sites was also detected by ApaI and 
SfoI RFLP assays in pDG459 Sox1B/Sox3B-trasfected cells (Fig. 2B and S1B). We next 
examined whether deletion of the sequences between the cut sites could be induced by 
pDG459 Sox1A/Sox1B or Sox3A/Sox3B transfection. PCR products corresponding to 
deletion alleles were readily generated in pDG459 Sox1A/Sox1B- or Sox3A/Sox3B-
treated samples but not in the WT and the unpaired controls upon Sox1 or Sox3 PCR (Fig. 
2B, S1C-D). Efficient dual nuclease activity was also demonstrated using pDG330- and 
pDG458-derived constructs (Fig. S2A-B). Together, these data indicate that all-in-one 
dual-gRNA Cas9 nuclease vectors can facilitate efficient simultaneous cutting at two 
gRNA target sites. 
 
Efficient DSBs induced by plasmids expressing Cas9-nickase and dual paired-gRNAs 
Expression of Cas9-nickase with a single gRNA results in a ssDNA break that is typically 
repaired without causing a mutation. In contrast, expression of Cas9-nickase and two 





DSB, repair of which results in indel mutations (Mali et al., 2013a; Ran et al., 2013a). We 
next tested the dual-gRNA Cas9-nickase vectors to assess whether they could efficiently 
induce DSBs via expression of gRNA pairs. We generated pDG462 derivatives targeting 
Sox1A/Sox1B and Sox3A/Sox3B which have the requisite orientation and spacing to 
permit mutagenesis by paired-nickase activity (Fig. 2A). As negative controls, we also 
generated pDG462 targeting Sox1A/Sox3A and Sox1B/Sox3B which are not paired 
therefore should not generate indel mutations. Vectors were transfected to mouse ES cells 
followed by puromycin selection. T7E1 heteroduplex assays revealed that pDG462 
Sox1A/Sox1B and Sox3A/Sox3B efficiently generated mutations at Sox1 and Sox3, 
respectively (Fig. 3 and S3). In contrast, there was no evidence of mutations after 
transfection of the non-paired control plasmids (Fig. 3 and S3). Efficient mutation of Sox3 
was also achieved using dual-gRNA nickase vectors pDG335 and pDG461 expressing 
Sox3A/Sox3B (Fig. S4). Together, these data demonstrate efficient targeted mutagenesis 
using dual-gRNA paired-nickase vectors. 
 
Discussion 
Plasmids from the Zhang laboratory have greatly simplified generation of customized 
gRNA-Cas9/Cas9-nickase expression constructs through utilization of the golden gate 
cloning strategy. Users only need to anneal a pair of oligonucleotides and ligate them into 
the vectors via a one-step cloning process, circumventing multiple rounds of PCR and 
cloning (Cong et al., 2013; Ran et al., 2013b). We modified available plasmids to allow 
simultaneous insertion of two oligonucleotide duplex inserts using the simple one-step 
cloning method. These modified vectors provide a user-friendly and cost effective system 
to perform experiments that require simultaneous expression of two gRNAs. Additionally, 





efficiency at both target sites when combined with reliable transfection and selection 
methods.  
Other recent studies have also generated CRISPR/Cas9 vectors that are able to express 
dual-gRNAs simultaneously, most of which also take advantage of golden gate cloning. 
However, unlike the dual-gRNA vectors described herein, these require multiple rounds of 
cloning and/or PCR (Kabadi et al., 2014; Maddalo et al., 2014; Sakuma et al., 2014; 
Vidigal and Ventura, 2015). Additionally, the strategy to express dual-gRNA as a 
polycistronic transcript that is split by Csy4 RNA polymerase (Tsai et al., 2014) has been 
shown to have low efficiency (Han et al., 2017). Furthermore, our dual-gRNA vectors are 
available with Cas9 nuclease or nickase, and with or without selection markers, and can 
therefore be utilized in a broad range of experimental contexts. Vectors from other studies, 
although more complicated, are useful when conducting experiments requiring more than 2 
gRNAs since those vectors can bear up to 7 gRNAs in a single vector (Kabadi et al., 2014; 
Sakuma et al., 2014). 
Our one-step cloning strategy could be applied to generate multiple gRNAs by adding 
more hU6-gRNA cassettes. To do so, the BbsI sites of the new cassettes would need to be 
modified to produce different unique overhangs upon digestion. This cloning approach 
could also be combined with other commonly used CRISPR platform variants such as 
Cpf1, dCas9-Fok1, Cas9-HF, eSpCas9, and other Cas9 orthologs or mutants that recognize 
different PAM sequences. 
Off-target mutagenesis is one of the most significant issues of CRISPR/Cas9 genome 
editing (Fu et al., 2013; Hsu et al., 2013), particularly for therapeutic applications. The 
paired-nickase strategy has previously been shown to minimize the off-target effects that 





anticipate that the dual-gRNA nickase vectors will be an attractive option for users who 
require efficient mutagenesis and with maximum specificity. 
Efficient dual nuclease cuts are useful for generating targeted large deletions for many 
purposes such as studying the function of enhancers or long non-coding RNA. In some 
situations, targeted large deletions are required to delete an exon such as for DMD 
therapeutics via exon skipping (Long et al., 2016; Nelson et al., 2016; Tabebordbar et al., 
2016) or to delete a centromere for chromosome removal (Adikusuma et al., 2017b). Dual-
gRNA Cas9 vectors could also be used for simultaneous KO of two different genes. We 
also offer our dual-gRNA nuclease vectors for efficient generation of chromosome 
translocations to model diseases such as Burkitt’s lymphoma or acute myeloid leukemia 
(Maddalo et al., 2014). Dual DSBs may also aid insertion of flanking loxP sequences for 
conditional deletion and for insertion of gene swap constructs (Adikusuma et al., 2017a; 
Quadros et al., 2017).  Furthermore, these vectors can also be used for injection into mouse 
zygotes for the generation of mutant mice (Mashiko et al., 2013). Taken together our 
vectors are a valuable addition to the CRISPR/Cas9 toolbox and should be useful for many 
CRISPR/Cas9-based applications. 
 
Materials and Methods 
Plasmid and gRNA design 
Plasmids pX330, pX335, pX458, pX459.V2.0, pX461 and pX462.V2.0 were gifts from 
Feng Zhang (Addgene plasmid 42230, 42335, 48138, 62988, 48140 and 62987, 
respectively). The Cas9 or Cas9-nickase of those plasmids are derived from Streptococcus 
pyogenes Cas9 which recognizes NGG PAM sequences. The BbsI sequences from pX330 





region was then amplified using primers containing NotI sites. PCR products were then 
ligated to original plasmids at the NotI site. Guide sequences targeting Sox1A, Sox1B, 
Sox3A and Sox3B were 5’-GCCGCCGGGCGAGTGCAGGT-3’, 
5’-GCCCACGAACCTCTCGGGCC-3’, 5’-GCTGACCCACATCTGAGCTC-3’ and 
5’-GACCGCAGTCCCGGCGCCC-3’, respectively, which were designed using online 
CRISPR design tool http://crispr.mit.edu/. 
 
One step cloning for the generation of customized dual-gRNA plasmid  
Forward and reverse oligonucleotides containing the guide sequences for Sox1A, Sox1B, 
Sox3A and Sox3B with appropriate overhangs (see Fig 1B) were phosphorylated and 
annealed by mixing 100 pmol of each pair and 0.5 µL T4 PNK (NEB) then incubated at 37 
°C for 30 minutes, 95 °C for 5 minutes and slowly ramped to RT. Annealed 
oligonucleotides were diluted 1 in 125. Pairs of oligonucleotide duplexes were ligated into 
the empty vectors in a one-step digestion ligation reaction by mixing the diluted duplex 
oligonucleotide pairs (1 µL each) with 100 ng empty vector, 100 µmol of DTT, 10 µmol of 
ATP, 1 µL of BbsI (NEB), 0.5 µL of T4 ligase (NEB) and NEB-2 buffer in 20 µL of 
reaction. The mixture was placed in a thermocycler and cycled 6 times at 37 °C for 5 
minutes and 16 °C for 5 minutes before bacterial transformation. Plasmids were prepared 
using miniprep kit (Qiagen) or PureLink® HiPure Plasmid Midiprep Kit (Life 
Technologies). Correct insertion of oligonucleotide duplexes into the vectors was 
confirmed by Sanger sequencing using the following primers: 
GGTTTCGCCACCTCTGACTTG (first insert) and TGCATCGCATTGTCTGAGTAGG 
(second insert). It is recommended to digest the vectors using BbsI before sequencing as 
correct insertion should remove the BbsI sites. List of oligo sequences that were used to 






Cell culture and transfection 
R1 mouse embryonic stem cells were used for all experiments. Cells were cultured in 15% 
FCS/DMEM supplemented with LIF, 3 µM CHIR99021 (Sigma), 1 µM PD0325901 
(Sigma), 2 mM Glutamax (Gibco), 100 µM non-essential amino acids (Gibco) and 100 µM 
2-mercaptoethanol (Sigma). One million ES cells were nucleofected with 3 µg of plasmid 
DNA using the Neon™ Transfection System 100 µL Kit (Life technologies) at 1400 V, 10 
ms and 3 pulses according to the manufacturer’s protocol. For transfection of pDG459 and 
pDG462, puromycin selection (2 µg/mL was initiated 24 hours post transfection for 48 
hours. GFP FACS was performed on cells transfected with pDG458 and pDG461 48 hours 
post transfection. Surviving cells were cultured for 4-7 days without selection before 
harvesting. Cells transfected with plasmid pDG330 and pDG335 did not undergo any 
selection. 
 
DNA extraction, PCR, RFLP and T7E1 assay 
Genomic DNA was extracted from 1-2 million cells using High Pure PCR Template 
Preparation Kit (Roche) according to the manufacturer’s instructions. Sox1 PCR was 
performed using primers F: 5’-CCCTTCTCTCCGCTAGGC-3’ and R: 
5’-GTTGTGCATCTTGGGGTTTT-3’. Sox3 PCR used primers F: 
5’-CAGCATGTACCTGCCACCT-3’ and R: 5’-ACAAAACCCCGACAGTTACG-3’. 
RFLP or T7E1 assay was performed by mixing 5 µL of PCR products (without 
purification) with the restriction enzymes or T7E1 enzyme (NEB) in a total volume of 20 
µL and incubated for 1 hour at the suggested optimal temperatures. Prior to T7E1 assay, 
PCR products were slowly re-annealed to form heteroduplex products by heating the PCR 
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Figure 1 | Generation of dual-gRNA expressing vectors. (A) Schematic of dual-gRNA 
vectors. (B) Golden gate cloning strategy for insertion of specific guide sequences into 
each cassette.  Note that the BbsI sites generate different overhangs after restriction digest. 
Red highlights indicate the BbsI sites, yellow and green highlights are part of hU6 
promoter and gRNA, respectively, that are necessarily present in the plasmid. Blue and 
purple highlights indicate the unique customized guide sequences (C) One-step cloning 
protocol for the generation of customized dual-gRNA vectors. (D) Insertion of Sox1A and 
Sox3A oligonucleotide duplexes into pDG459 resulted in correct insertions in all 12 
colonies as indicated by BspMI and SacI restriction digest. The black arrow indicates the 







Figure 2 | Efficient dual cutting mediated by pDG459 vector. (A) Schematic of gRNA 
target sites in the Sox1 and Sox3 genes. (B) Highly efficient dual cuts induced by vectors 
derived from pDG459 as indicated by PCR and RFLP analyses. WT products were cut by 
restriction enzymes resulting in bands indicated by the red arrows. Absence of these bands 
in dual-gRNA vector-treated samples indicated that the Cas9 nuclease and the gRNAs 
efficiently induced mutations thus destroying the restrictions sites. Efficient cuts from 
pDG459 Sox1A/Sox1B and pDG459 Sox3A/Sox3B were indicated by deletion of ~50 bp 
regions between cuts (blue arrows). Complete figures with more independent samples can 







Figure 3 | Paired-nickase DSB induction by pDG462. Sox1 or Sox3 PCR followed by 
T7E1 assay was performed on pDG462-transfected samples. Mutations in Sox1 and Sox3 
were induced by pDG462 Sox1A/Sox1B or pDG462 Sox3A/Sox3B, respectively, as 
indicated by the digested products after T7E1 treatment (blue arrows). Mutations were not 
induced by non-paired-nickase control plasmids (pDG462 Sox1A/Sox3A or pDG462 
Sox1B/Sox3B). Complete figures with more independent samples can be found in 








Figure S1-S4 and Table S1 
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Supplementary Figure S1 | Efficient dual cutting mediated by pDG459 vector, 
extended figures of Fig. 2B with more independent samples. (A) BfuAI and SacI RFLP 
analyses indicated efficient dual cuts from pDG459 Sox1A/Sox3A. (B) ApaI and SfoI 
RFLP analyses indicated efficient dual cuts from pDG459 Sox1B/Sox3B. WT products 
after digestions (red arrows) were absent in pDG459-treated samples. (C) Large deletions 
were induced in the Sox1 region in pDG459 Sox1A/Sox1B-treated samples. (D) Large 
deletions were induced in the Sox3 region in pDG459 Sox3A/Sox3B-treated samples. 
Large deletion fragments are indicated with blue arrows. Each sample came from 







Supplementary Figure S2 | Mutation inductions mediated by vectors pDG330 and 
pDG458. (A) Transfection of pDG330 Sox1A/Sox3A into mouse ES cells induced 
mutations at both targets which were indicated by smaller fragments after T7E1 assay 
(blue arrows). (B) BfuAI and SacI RFLP were used to assess the mutation induction in 
Sox1A and Sox3A sites, respectively, after treatment of pDG458 Sox1A/Sox3A followed 
by GFP FACS enrichment. Presence of WT products produced smaller bands after 
restriction digestions (red arrows) which were absent in pDG458 Sox1A/Sox3A-treated 








Supplementary Figure S3 | Paired-nickase DSB induction by pDG462, extended 
figures of Fig. 3 with more independent samples. Smaller bands produced after T7E1 
digestion (blue arrows) indicated presence of mutation in samples treated with paired-
nickase pDG462 Sox1A/Sox1B (A) or Sox3A/Sox3B (B). Each sample came from 







Supplementary Figure S4 | Paired-nickase-mediated mutation inductions by pDG335 
and pDG461 vectors. T7E1 assay showed that expression of paired-nickase gRNAs 
Sox3A/Sox3B from pDG335 (A) or pDG461 (B) induced mutations in the Sox3 locus as 
indicated by the presence of cut products (blue arrows). Each sample came from 
independent transfections. 
 
Supplementary Table S1 | List of oligos used to generate the dual-gRNA targeting 
plasmids 
Target Oligo pair 1 (5’-3’) Oligo pair 2 (5’-3’) 
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breaks frequently generate 








Given that Thomas laboratory routinely uses CRISPR/Cas9 to generate mutant mouse 
model by zygote injection, comprehensive assessment of the mutation efficiency needs to 
be established. In this study, six different biallelic loci were assessed and screened for 
mutations using heteroduplex assays and Sanger sequencing, both of which involved 300–
600 bp PCR amplification. Heteroduplex screening of 137 samples indicated that 
mutations were present in only 61% of samples. Surprisingly, more comprehensive 
screening, including Sanger sequencing, revealed that 97% of samples contained 
mutations. The high false negative rate in the heteroduplex assay was caused, 
unexpectedly, by large deletion mutations in one allele, which prevented PCR 
amplification and therefore heteroduplex formation. By performing larger PCR (~1.6-3.2 
kb) amplifications of all samples, it was observed that 41% samples had large deletions of 
>100 bp. This is unusual, as repair of a single DSB generated by Cas9 is thought to use 
non-homologous end joining mechanism resulting in small indel mutations. The formation 
of these large deletions induced by CRISPR/Cas9 DSB was further studied in mouse ES 
cells. With the five gRNAs tested, frequent large deletion mutations were consistently 
observed, as measured by qPCR analyses. Whole genome sequencing (WGS), which 
examines mutation outcomes in an unbiased manner, was also conducted to confirm these 
frequent large deletions. Surprisingly, WGS also detected frequent insertions of the 
CRISPR/Cas9 expression plasmid into the break sites. 
The large deletions found in mouse zygote injection samples were sequenced to 
characterise these deletions. Interestingly, the deletions were asymmetric relative to the 
break site and the break junctions contained predominantly 1–3 bp microhomology 
sequences, and in some cases small insertions or no microhomologies. Using a novel assay 





end resections. These characteristics suggested that alternative end joining (Alt-EJ) was the 
repair mechanism underlying the formation of these large deletions.  
A manuscript describing this study will be submitted for a publication to inform the 
scientific community that a single DSB can result in large deletions or plasmid insertion. 
This is crucial as failure to notice these frequent repair outcomes could result in misjudging 
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CRISPR/Cas9 genome editing has emerged as a powerful technology for generating 
targeted genomic modifications in a vast array of cellular contexts including cultured cell 
lines, zygotes and somatic cells. DNA double-stranded breaks (DSB) generated by 
CRISPR/Cas9 are commonly repaired by non-homologous end-joining (NHEJ) mechanism 
resulting in small indels. Unexpectedly, through analysis of 137 mice generated from 
CRISPR/Cas9 zygote injections, we identified large deletions (>100 bp) of up to 2.3 kb in 
56 (41%) of founders. Frequent large deletions were also generated in ES cells in response 
to CRISPR/Cas9-induced single-site DSBs. Unbiased whole genome sequencing (WGS) in 
pooled ES cells indicated that large deletions occurred in 37.5% of alleles.  Using a novel 
single-strand annealing (SSA) capture assay, we also show that large deletions are 
generated via DNA resection and that their breakpoint junctions contain microhomologies 
or insertions, indicating an alternative end-joining (Alt-EJ) mechanism. This study unveils 
underestimated yet common repair outcomes of endonuclease-mediated cleavage.  
Researchers should consider the possibility of large deletions to avoid misinterpretation of 






The CRIPSR/Cas9 genome editing platform has been developed from an adaptive 
immunity system in bacteria and archaea and comprises two components; Cas9, which 
functions as a programmable endonuclease that generates a blunt-ended double-stranded 
break (DSB) and a ~100 nt guide RNA (gRNA). The latter contains a ~20 nt guide 
sequence at the 5’ end that directs Cas9 to the target site via RNA:DNA complementary 
base pairing and an invariant ~80 nt sequence required for stabilization of the gRNA/Cas9 
complex. While modification of the guide sequence provides considerable flexibility in 
target site selection, there is also a strict requirement for a protospacer adjacent motif 
(PAM) sequence (NGG for SpCas9) adjacent to the DNA target sequence to which Cas9 
binds. CRISPR/Cas9 technology has emerged as the system of choice for many researchers 
to perform genome editing in many organisms due to its high efficiency, flexibility, ease of 
use and low cost (Cong et al., 2013; Hsu et al., 2014; Jinek et al., 2012; Komor et al., 2017; 
Mali et al., 2013; Sander and Joung, 2014).  
Genomic modification by CRISPR/Cas9 is achieved by relying on the cellular DNA repair 
mechanism to fix the breaks induced by the Cas9. The mechanism that is thought to 
predominate the repair of these DSBs is non-homologous end-joining (NHEJ) which 
typically generates small deletions (~1-20 bp) and in some cases short insertions (≤5 nt) at 
the cut site. Alternatively, specific targeted modifications can be introduced at the breaks 
through an accurate DNA repair mechanism called homologous recombination (HR) or 
homology directed repair (HDR) which requires addition of a ssDNA or dsDNA donor 
repair template containing homology arms flanking the mutation sequence to be copied 
(Cong et al., 2013; Hsu et al., 2014; Komor et al., 2017; Mali et al., 2013; Sander and 





In this study, we show that DNA repair after Cas9-induced DSBs does not exclusively 
result in small insertions and deletions (indels) as commonly perceived. Instead, our 
analyses reveal that large deletions (>100 bp) also appear to be a common outcome of 
CRISPR/Cas9 single-site cleavage in zygotes and pluripotent cells. These large deletions 
are generated via DNA end resection and often contain microhomology sequence tracts 
flanking their breakpoints suggesting an alternative end-joining (Alt-EJ) mechanism, also 
referred to as microhomology-mediated end-joining (MMEJ), which is promoted by DNA 
polymerase θ (Polθ) (Kent et al., 2015). Together, these findings expand our knowledge of 
the repair outcomes that occur in response to CRISPR/Cas9 cleavage and provide a useful 




High frequency of large deletions generated by CRISPR-Cas9 cleavage in zygotes 
To gain a more comprehensive understanding of the efficiency of CRISPR mutagenesis 
and modalities of DNA repair, we screened founder embryos and mice derived from 
CRISPR/Cas9-injected zygotes for mutant alleles.  Six loci were independently targeted for 
indel mutations using a single gRNA.  Three of the gRNAs targeted coding regions of 
autosomal genes which do not cause nullizygous lethality (Viperin, Pik3r6 and Hmgcs2) 
and three targeted intronic/flanking regions in Ngn3, Fzd3 and Foxp4 (Figure 1A). 137 
samples (embryos and mice) were initially screened using a polyacrylamide (PA) gel 
heteroduplex assay of a 0.3-0.6 kb PCR product spanning the gRNA target site (Chen et 
al., 2012).  In our experience, the PA heteroduplex assay provides similar reliability to the 
commonly used T7E1 heteroduplex assay but is easier to perform and less expensive. PA 





S1). These included samples with smaller PCR products than expected, suggesting that 
they contain deletions in the order of 100-300 bp. Notably, four samples failed to amplify 
(Figure S1, sample Foxp4 #1, #2, #9 and Fzd3 #29), indicating that they may have 
contained biallelic deletions that encompassed the PCR primer binding sites. To further 
characterize the mutations in each sample, we sequenced the PCR products including the 
“mutation-negative” samples. As expected, small indels were detected in all PA gel 
heteroduplex-positive samples. 87% of the sequenced samples contained at least two 
mutant alleles, while heterozygous (i.e. “single hit)” mutations were only observed in the 
remaining 13% (Table S1). Surprisingly, 88% of heteroduplex-negative samples that we 
sequenced contained a small indel as opposed to the WT sequence (Table S1). Only one 
type of mutation was observed in these samples which explained why they were not 
detected by heteroduplex assay (false negatives). While it is possible that both alleles carry 
the same mutation, this is unlikely given the range of indels that were detected in each 
group of founders.  
An alternative possibility is that one allele has a small indel while another has a large 
deletion that eliminates one or both primer binding sites thereby preventing PCR. To 
investigate this possibility, we performed ~1.6 kb PCR using primers equidistant from 
gRNA-PAM sequences. Surprisingly, we found that 34% of samples generated amplicons 
that were smaller than expected indicating alleles with large (>100 bp) deletions (Figure 
1C, Figure S2A and Table S2). Additional large deletion products were generated when we 
performed a 3.2 kb PCR on Ngn3 and Foxp4 samples (Figure S2B and Table S2). Large 
deletions were detected in heteroduplex-negative samples as well as heteroduplex-positive 
samples, indicating mosaicism alleles in the latter samples. We could also generate 
products from samples that failed to amplify in the initial 0.3-0.6 kb PCR, confirming that 
these contained large deletion alleles (Figure S1 and S2, sample Foxp4 #1, #2, #9 and Fzd3 





products. Up to this point, we could identify large deletion alleles in 41% of samples with 
some founders harboring more than one large deletion event (Table S2). The size of large 
deletions (after ~1.6 kb PCR) ranged from 100-800 bp (Figure 3 and Figure S2). The 
largest deletion found in this experiment was 2.3 kb that we detected in a Foxp4 sample 
after 3.2 kb PCR (Figure S2B, sample Foxp4 #19). Combining these large deletion data 
with the heteroduplex assay and Sanger sequencing analyses, we found that 133 of 137 
(97%) of founders contained at least one mutation, a very high efficiency compared to the 
other published studies (Shen et al., 2013; Wang et al., 2013; Yang et al., 2013; Zhang et 
al., 2016). 
 
High frequency of large deletions generated by CRISPR-Cas9 cleavage in mouse ES 
cells  
To further study the frequency and large deletions, we performed additional experiments 
using mouse embryonic stem cells (mESC). PX459.V2.0 expression constructs encoding a 
single gRNA and Cas9 were transiently transfected and puromycin-resistant transfectants 
were harvested for genomic DNA (gDNA) extraction.  Single gRNAs targeting autosomal 
(Ngn3, Sox1 and Viperin) and single copy X-linked (Sox3) loci were selected for analysis. 
RFLP-based genotyping (for Sox1, Viperin and Sox3) and TIDE analysis (for Ngn3) 
indicated close to 100% cutting efficiency in harvested cell pools (Figure S3A-D). This 
high cutting efficiency permitted accurate quantification of large deletion events by qPCR 
of pooled genomic DNA using primers that bind >100 bp from the cutting sites. For each 
gRNA, two qPCRs were performed to cover large deletions occurred at both upstream and 
downstream regions of the cutting sites (Figure 2A). We reasoned that deletion of primer 
binding sites due to a large deletion would result in reduction of qPCR signal. 





a negative control gRNA targeting the bacterial neomycin resistance gene (Neo gRNA). 
The reduction in qPCR signal ranged from 14-30% with an average of 24% and 23% 
reduction in the upstream and downstream qPCR, respectively (Figure 2A). Given that 
unidirectional large deletions would reduce qPCR signal for only one of the flanking qPCR 
reactions, whereas bidirectional deletions would reduce signal for both qPCR reactions, we 
conclude that the frequency of large deletion events is between ~23% (all bidirectional) 
and ~47% (all unidirectional). Notably, these large deletions were also generated when 
DSBs were induced with 5’ overhang sticky-ended cuts via double Cas9-nickase (Cas9n) 
as observed by qPCR analyses (Figure S4).  
As detection of large deletions using PCR is prone to amplification bias and is confounded 
by deletion of primer sequences, we next sought to use an unbiased approach to determine 
the frequency and extent of CRISPR/Cas9-induced large deletions in ESC. We performed 
PCR-free paired-end whole genome sequencing (WGS) analysis on gDNA from Viperin 
gRNA-transfected ESCs. From a total of 88 sequence reads, only two reads (2.3%) 
corresponded to WT alleles, consistent with the high mutagenesis efficiency as shown by 
RFLP analysis (Fig. S3D). Small indels and substitutions were found in 33 reads (37.5%), 
while large deletions inferred from discordant mapping of paired-end reads and split read 
mapping over the breakpoint were also detected in 33 reads (37.5%) (Figure 2B). The 
remaining 20 (23%) unexpectedly contained insertions of the PX459.V2.0 expression 
plasmid. Taken together, these data confirm that large deletions are frequently generated 
after CRISPR/Cas9-mediated DNA cleavage in ESC and mouse zygotes. 
 
Random large deletions contain microhomology and are initiated by DNA resection 
To investigate the mechanism of large deletion generation, we sequenced 59 of the large 





FoxP4, Fzd3, Viperin, Pik3r6 and Hmgcs2 gRNAs described (Figure S2A), including the 
large deletions generated by two other gRNAs targeting Kcnt1 and the Sox3. Each gRNA 
generated a range of unique deletions indicating that the process underpinning generation 
of large deletions is stochastic (Figure 3A). Indeed, we only found two examples of 
independent founders carrying the same deletion. Assessment of the breakpoint sequences 
revealed that the vast majority of junctions contained microhomology (MH) of 1-3 bp 
(63%) or longer (22%). Junction sequences with short insertions (predominantly 1-2 bp 
insertions) or no homology were also present in low abundance (Figure 3A and 3B). We 
observed, interestingly, that the orientation of the large deletions was noticeably 
asymmetric/unidirectional with respect to the cutting site (Figure 3A). Indeed, only 4 of 59 
random large deletions were obviously bidirectional (>100 bp to both directions) (Figure 
3A).  
Together, these characteristics suggested Alt-EJ as the repair process underlying the 
formation of large deletions. Alt-EJ is characterized by the presence of MH or insertion at 
the repair junction. It usually results in relatively large deletions and is thought to be 
promoted by DNA end resection (Black et al., 2016; Chang et al., 2017; Deriano and Roth, 
2013).  To determine whether the generation of large deletion requires end resection, we 
developed a single-strand annealing (SSA) trapping assay at an endogenous locus in mouse 
ES cells. In this assay, DNA end resection following a single DSB traps the cell into using 
SSA repair mechanism due to the presence of flanking repeat sequences (Bhargava et al., 
2016). We used the Nprl2-SSA gRNA to generate a DSB within a 9 bp spacer sequence 
located between two 34 bp perfect repeats in mouse Nprl2 gene. We reasoned that DNA 
resections of >43 nt would be trapped into a SSA repair event generating a 43 (34 + 9) bp 
deletion (Figure 3C). Indeed, PCR analysis of Nprl2-SSA gRNA expressing cells indicated 
a high frequency of the 43 bp SSA-deletion repair event which was confirmed by Sanger 





another highly efficient DSB was generated outside of the repeat sequences using gRNA 
Nprl2-out (Figure 3C and S5C), which did not generate the 43 bp SSA-deletion repair 
event (Figure 3D). As expected, DNA breaks from gRNA Nprl2-out produced frequent 
large deletions as determined by qPCR (Figure 3E). In contrast, DSB induced by gRNA 
Nprl2-SSA failed to generate large deletions, indicating that trapping the DNA resection 
intermediate into SSA repair prevents the generation of the large deletions (Figure 3E). 
Taken together, these data suggest that the Alt-EJ mechanism underpins the generation of 
large deletions.  
 
Discussion 
From this study, we again witness the remarkable efficiency of the CRISPR/Cas9 system 
in generating DSB-induced mutations in mammalian cells. WT samples/alleles were rarely 
detected after mouse zygote injections or ESC transfections, as has also been observed by 
others (Bell et al., 2014; Wang et al., 2013). The high mutagenic efficiency of all gRNAs 
used in this study contrasts with their average on-target score (Table S3 and S4), arguing 
against the necessity for selecting gRNAs based on their on-target efficiency score 
(Doench et al., 2016). Rather, this study underlines the importance of microinjectionist 
skill in delivering high quality CRISPR reagents into zygotes and the development of 
effective transfection strategies for efficient mutagenesis in mice and cells, respectively.  
Here, we also learnt about the significant disadvantage of relying exclusively upon PCR 
heteroduplex formation assays for mutation screening of founder animals. The high 
frequency of biallelic mutations that included a large deletion event resulted in a very high 
false negative rate. Mixing and reannealing of founder and WT PCR products would 
circumvent this problem and should be considered as the primary screening assay for 





cut site, is also a useful screening tool, provided that a suitable restriction site is available. 
Direct sequencing of the PCR product is probably the most definitive method, although 
this is significantly more expensive than other options.    
A key finding of this study is that DSB generated by CRISPR/Cas9 endonuclease activity 
are frequently repaired via a mechanism that generates large deletions flanking the 
cleavage site. This finding contrasts with the common perception that CRISPR/Cas9-
mediated breaks are almost exclusively repaired by NHEJ resulting in small indels. 
Deletion of PCR primer binding sites is probably the most significant factor contributing to 
the underappreciation of large deletion frequency.  We find that large deletions are 
unexpectedly common, occurring in 41% of founder mice across 6 loci. This frequency is 
likely an underestimate as further separation of the genotyping PCR primers (beyond 3.2 
kb) would likely reveal additional large deletions.  Mouse ES cells also exhibit a high 
frequency of large deletions, as determined by qPCR (23 - 47%) and unbiased WGS 
analysis (37.5%.), demonstrating that the mechanism that leads to large deletions is not 
restricted to totipotent cells.  Indeed, recent reports have also identified frequent large 
deletions in mouse zygotes (Shin et al., 2017; Zhang et al., 2016), as well as mouse 
embryonic brains (Zuckermann et al., 2015) and mouse NIH-3T3 (transformed fibroblast) 
cells (Mou et al., 2017). Moreover, large deletion repair outcomes are also found in DSB 
induced by other nucleases such as TALENs and IsceI, suggesting they are general feature 
of DSB repair (Cheng et al., 2016; Honma et al., 2003). Together these studies suggest that 
large deletions will be generated in many cell contexts and researchers should be alert to 
the possibility that their occurrence may lead to inaccurate genotyping, especially in cell 
lines (as opposed to mice) where it is not possible to segregate mutant alleles via breeding. 
How are large deletions generated in zygotes and ESC? One well-known DNA repair 





2016).  This mechanism can be used to repair DSBs that occur between long repeat 
sequences.  5’-3’ resection of the DSB allows the complementary single-stranded repeat 
sequences to bind each other creating a deletion of the intervening region. Thus, SSA 
repair products contain a long homology sequences in the breakpoint junctions and the 
deletion size depends on the distance between the flanking repeats (Bhargava et al., 2016). 
In contrast, the large deletions observed in this study were random in size and position, and 
the junctions contain only short tracts of microhomology (mostly 2-3 bp) or small 
insertions, which are typical signatures of Alt-EJ. Through development of an endogenous 
SSA trapping assay, we demonstrated that DNA repair initiated by end resection is 
frequent, and that these large deletions also require DNA end resection to form. Together, 
these data suggest that the repair mechanism underlying the formation of large deletions is 
a poorly defined Alt-EJ repair mechanism (Bhargava et al., 2016; Black et al., 2016; Chang 
et al., 2017; Deriano and Roth, 2013). The high frequency of large deletions supports the 
notion that Alt-EJ is not exclusively a backup pathway, but it is also active when NHEJ 
repair process is available (Sfeir and Symington, 2015). The high frequency of apparent 
Alt-EJ may be influenced by the absence of HR pathway in our experiments. It might be 
interesting to test whether large deletion frequency is altered when HR is available since 
Alt-EJ and HR repair both share the initial end resection process and are active at the same 
phases of the cell cycle, S and G2 (Bhargava et al., 2016; Deriano and Roth, 2013). In Alt-
EJ, repair of DSBs is initiated with 5’-3’ DNA end resection by the MRN complex 
together with CtIP resulting in 3’ ssDNA overhangs (Chang et al., 2017; Sfeir and 
Symington, 2015). The key factor in Alt-EJ, Polθ, promotes transient annealing between 3’ 
ssDNA overhangs via the use of microhomology sequences (Kent et al., 2015). Any 
excessive remaining 3’ overhangs at the DNA synapse are likely cleaved by an unknown 
nuclease before the next steps take place. The minimally paired overhangs are extended by 





are filled, the DNA end-joining intermediate is ligated by Lig1 or Lig3 (Black et al., 2016; 
Deriano and Roth, 2013; Simsek et al., 2011). One study estimated that Alt-EJ was 270 
times more common than HR repair of DNA DSB in human cells (Honma et al., 2003). It 
is therefore possible that the low frequency of intended HDR that is commonly observed in 
mice and cells (Adikusuma et al., 2017a) is due to successful competition by Alt-EJ 
(Zelensky et al., 2017). Therefore, attempts to increase HDR frequency should consider 
repressing this repair pathway (Zelensky et al., 2017) in addition to repressing NHEJ (Chu 
et al., 2015; Maruyama et al., 2015; Robert et al., 2015; Yu et al., 2015). 
It is intriguing to consider how the 3’ overhang sequences generated by DNA resection 
select target sequences for microhomology base pairing given the abundant options that are 
available. We found that 2-3 nt microhomologies predominated at the breakpoint junctions 
of large deletions, although 1 nt microhomology was also observed. While longer 
microhomologies ≥2 bp generate more stable transient DNA synapses that are rapidly 
accommodated by Polθ to intiate Alt-EJ (Kent et al., 2015), the infrequent availability of 
these microhomologies at the right time and position might account for their relative 
paucity in large deletion sequence junctions. Besides promoting microhomology-mediated 
end-joining between DNA overhangs, Polθ also possesses terminal transferase activity that 
can extend the overhangs during the end-joining process (Kent et al., 2016). Terminal 
extension before microhomology annealing and DNA replication will create novel 
sequences that result in insertions at DNA repair junctions. This terminal transferase 
activity is likely responsible for the occasional small insertions we detected at the large 
deletion junctions (Kent et al., 2016). In the case of 0 microhomology, it is possible that 
the Polθ -mediated extension generates chance microhomology, such annealing of the 






One interesting characteristic of the large deletions is that they typically extend in only one 
direction from the cut site (i.e. they are unidirectional/asymmetric). Relatively asymmetric 
large deletions were also recently observed in C. elegans (at G4 break site) (Koole et al., 
2014), in human cells (Isce1-induced DSB) (Honma et al., 2003) and in mice (Cas9 
breaks) (Zuckermann et al., 2015). Studies in C. elegans indicated that Polθ was 
responsible for this unidirectional large deletion, again supporting Alt-EJ as the repair 
mechanism underlying the large deletions identified in our study (Koole et al., 2014; van 
Schendel et al., 2015). These unidirectional deletions suggest that annealing occurs 
between the terminal sequences of 3’ overhang with the microhomology complementary 
sequence located a significant distance away from the break site. This is supported by in 
vitro analysis which showed efficient Polθ-mediated microhomology annealing between 
terminal and internal sequences (Kent et al., 2015; Wyatt et al., 2016). This activity 
requires trimming of DNA overhang flap on only one side during the process. The 
directionality of the deletion (upstream or downstream from the break) depends on which 
3’ overhang uses the terminal sequences and which 3’ overhang use the internal sequences 
during the microhomology annealing step. When annealing occurs between terminal 
sequences of 3’ overhang sense strand with microhomology internal sequences of 3’ 
overhang antisense, a large deletion of the downstream sequence is generated, and vice 
versa.  We hypothesize that there is competition between sense and antisense 3’ overhang 
strands for annealing of their terminal sequences which we term the Strand Competition 
for Annealing after Resection (SCAR) effect (Figure 4A). Stochasticity of the proposed 
SCAR effect provides an explanation for the variation in orientation and extent of the large 
deletions that we identified for each gRNA.  
We propose two possible mechanisms to explain the (relatively rare) bidirectional large 
deletions (Figure 4B-C). Microhomology annealing after resection could occur between 





both sides need to be trimmed to allow subsequent steps of DNA extension and ligation. In 
vitro study showed this scenario was inefficient (Kent et al., 2015; Wyatt et al., 2016). The 
second possibility is that relatively longer resection can occur in 3’-5’ direction (Dorsett et 
al., 2014). Microhomology-mediated annealing of terminal sequences of the 3’-5’ resected 
3’ overhang with internal sequences of opposite 3’ overhang would result in bidirectional 
large deletions. In this scenario, excessive flap trimming only occurs on one side (Figure 
4C).   
In addition to the observation of frequent large deletion, we also surprisingly observed 
frequent plasmid integration to the break site from WGS analysis. It is still unclear how 
circular DNA integrates to the DSB, but it likely involves HDR. Targeted integration of 
homology-independent linear DNA has been known to be quite efficient in combination 
with CRISPR/Cas9 breaks (Hisano et al., 2015; Suzuki et al., 2016). Interestingly, Polθ 
was recently shown to play a major role in facilitating off-target or random DNA 
integration in mice and human cells (Zelensky et al., 2017). We suspect the plasmids 
underwent linearization inside the cells before integrating to the break sites which likely 
explains the phenomenon of random stable integration of circular plasmids into the 
genome. This integration of homology independent plasmid to the break sites should be 
considered as a DNA repair outcome when conducting experiments using plasmid-based 
expression vectors. It will be interesting to know how the pattern of DNA repair outcomes 
in the absence of plasmids, whether repairs resulting in more large deletions, more small 
indels or equally distributed to both repair outcomes. Further study by delivery of Cas9 and 
gRNAs in RNA or protein form is needed to address this question. 
In summary, our data revealed that in addition to small indels, DNA DSBs in particular 





insertions. We caution researchers to consider these repair outcomes when performing 
CRISPR/Cas genome editing experiments to avoid misinterpretation of the true genotype. 
 
Experimental procedures 
Generation of gRNA, Cas9 mRNA and expression plasmids 
gRNAs (Table S3 and S4) were designed using CRISPR designing tool from Zhang lab 
MIT http://crispr.mit.edu. On-target scores were calculated using CRISPOR gRNA design 
tool (Haeussler et al., 2016) based on algorithm developed by Doench et al. (Doench et al., 
2016). Most of the gRNAs for zygote injections were generated in house using the protocol 
described by Wang et al. (Wang et al., 2013). In brief, a pair of oligo containing target 
sequences was ligated to BbsI-linearized PX330 plasmid and was used as PCR template to 
produce T7-gRNA PCR products. T7-gRNA PCR products were PCR purified (Qiagen) 
and were then used for IVT template to produce the gRNAs using HiScribe T7 (NEB). 
gRNAs for Pik3r6 and Hmgcs2 were purchased from ToolGen. Cas9 mRNA was produced 
by IVT of XhoI-linearized Cas9 vector (ToolGen) using mMessage T7 ultra kit (Ambion). 
All RNAs were purified using Rneasy mini kit (NEB). For experiments in mouse ES cells, 
PX459.V.2.0 was used as gRNA and Cas9 expression plasmid as described by Ran et al. 
(Ran et al., 2013). For expression of Cas9-nickase (Cas9n) and dual gRNAs, plasmid 
PX462.V.2.0 was modified by cloning an extra gRNA expression cassette to NotI site of 
the plasmid as described by Adikusuma et al. (Adikusuma et al., 2017b). Thus, all 
components (Cas9n, gRNA 1, gRNA 2 and puromycin selection marker) were expressed 
from a single plasmid. Plasmid preparations were performed using PureLink® HiPure 






Mouse zygote injections 
All animal procedures have been approved by The University of Adelaide Animal Ethic 
Committee. Cas9 mRNA (100 ng/µL) and gRNAs (50 ng/µL each) were injected into the 
cytoplasm of C57BL/6N zygotes using a FemtoJet microinjector, transferred to pseudo 
pregnant recipients and allowed to develop to term or harvested as embryos. Injections of 
Sox3 gRNA was accompanied with single-stranded oligo donor. 
 
DNA extraction, PCR, genomic qPCR, heteroduplex assay and RFLP  
Genomic DNA was extracted from tail tissue or ES cells (1-2 million) using High Pure 
PCR Template Preparation Kit (Roche) according to the manufacturer’s instructions. PCRs 
were mostly conducted using FailSafe™ PCR System (Epicentre). qPCRs were performed 
using Fast SYBR Green Master Mix (Applied Biosystems) on an Applied Biosystems 7500 
StepOnePlus machine. Statistical analysis was performed using Student’s two tailed 
unpaired t-tests in GraphPad Prism software. Heteroduplex assay or RFLP was conducted 
following 0.3-0.6 kb PCR. For heteroduplex assay, PCR products were heated 95° C for 3 
minutes and cooled down slowly to room temperature (0.1° C/s) prior to gel 
electrophoresis on 12% non-denaturing polyacrylamide gel for 2 hours at 150 V. RFLP 
was performed by incubating 5 uL of PCR products (without purification) in a total volume 
of 20 µL digestion reaction containing the relevant buffers and restriction enzymes (NEB) 









Sequencing and TIDE analysis 
For sequencing, PCR products were purified using QIAquick PCR Purification Kit 
(Qiagen) and directly sequence using the forward or reverse primer of each PCR. For 
TIDE analysis, sequencing data was entered to TIDE online tool at https://tide.nki.nl/ 
(Brinkman et al., 2014). For large deletion sequencing, PCR products were separated on 
1% agarose gel. Visually smaller bands from the gel were cut and gel purified using 
QIAquick Gel Extraction Kit (Qiagen) before subjected for big dye sequencing reaction 
using the forward or reverse primers of each PCR.  
 
CRISPR/Cas9 plasmid transfection in mESc 
Cell culture and transfection followed the procedure described by Adikusuma et al. 
(Adikusuma et al., 2017b). R1 mouse embryonic stem cells were cultured in 15% 
FCS/DMEM supplemented with 2 mM Glutamax (Gibco), 100 µM non-essential amino 
acid (Gibco), 100 µM 2-mercaptoethanol (Sigma), 3 µM CHIR99021 (Sigma) 1 µM 
PD0325901 (Sigma) and LIF (generated in-house). One million of ES cells were 
nucleofected with 3 µg of plasmid DNA using the Neon™ Transfection System 100 µL 
Kit (Life technologies) at 1400 V, 10 ms and 3 pulses according to the manufacturer’s 
protocol. 24 hr after transfection, selection was conducted by adding puromycin (2 µg/mL) 
to the media for the next 48 hr. Surviving cells were cultured for 4-7 days without selection 
before harvesting.  
 
Whole genome sequencing 
Whole genome sequencing was performed using Illumina HiSeq X Ten system which was 





to their instructions. Sequence data were mapped to the GRCm38_68 build of the mouse 
genome with BWA-MEM 0.7.12-r1039.  Indels realignment and base quality score 
recalibration was performed using the genome analysis toolkit v3.6 using the mouse 
genomes project 129/SvlmJ v5 merged indel and dbSNP142 vcf files (Keane et al., 2011).  
SNP and indels were called using the genome analysis toolkit haplotype caller.  Larger 
insertions and deletions were called with DELLY (Rausch et al., 2012) and Manta (Chen et 
al., 2016).  Reads with discordant mapping indicative of large deletions, insertions, 
inversions and translocations specifically covering the PAM site within Viperin were 
extracted from the BAM file based on bitwise mapping flags using samtools-v1.2 
(samtools view) to quantify putative mutation events.  The identity of novel sequence 
insertions was by BLAST to the NCBI non-redundant sequence database. Sequence 
alignments were visualized with the integrative genome viewer (Robinson et al., 2011). 
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Figure 1. CRISPR/Cas9-mediated Breaks in Mouse Zygote Injection 
(A) Experimental flow of mouse zygote injection experiment. Six independent zygote injections targeting 
biallelic sequences produced 137 samples that were analyzed by PA gel heteroduplex assay, Sanger 
sequencing and large PCR (~1.6 kb). (B) Example of PA gel heteroduplex assay with ~400 bp PCR in Fzd3 
mouse samples. Complete figures from all injections can be found in Figure S1. * = Samples containing 
heteroduplex generate extra bands besides the WT-sized bands. ^ = Sample that cannot be amplified which 
was found to have large deletion when larger PCR was performed. + = heteroduplex positive control. (C) 
Example of ~1.6 kb PCR in Ngn3 samples. Complete figures can be found in Figure S2A. $ = Samples that 






Figure 2. Detection of large deletions after CRISPR/Cas9-mediated breaks in pooled mouse ES cells 
(A) Large deletions after CRISPR/Cas9 breaks were detected by qPCR using primers located >100 bp away 
from the cutting sites. Two qPCRs were conducted for each DSB, on the upstream (left) and downstream 
(right) relative to the NGG PAM sequences. Neo gRNA as control. Internal reference qPCR used Sox1-
3’UTR qPCR, except for Sox1-left or Sox1-right qPCR which used Sox2 qPCR. Data are presented as mean ± 
SEM (n ≥ 3). ***P<0.001; ****P<0.0001. (B) Whole genome sequencing analysis to Viperin gRNA-treated 
mouse ES cell pools. Integrative genome viewer snapshot shows reads paired in sequencing and sorted by 







Figure 3. Characteristics of large deletions 
(A) Sequencing of large deletion bands after ~1.6 kb PCR from mouse zygote injection samples. 0 represents 
the cutting site of Cas9. Each bar represents the deletion position relative to the NGG PAM sequences. 
Microhomologies or insertions in the break junction are indicated by sequences with black and red font, 
respectively. (B) Percentage of large deletion with MH or insertions. (C) Schematic of SSA trapping assay. 
(D) PCR across the cutting sites showed an extra band of 43 bp deletion after Nprl2-SSA gRNA cuts but not 
in other controls. Four biological replicates for each gRNA. M = marker. (E) Genomic DNA qPCR 
quantification using primers FL+RL (left figure) and FR+RR (right figure) as indicated in (C). Data were 








Figure 4. Mechanism of alternative end-joining generating large deletions  
(A) Mechanism of unidirectional/asymmetric large deletions. (B) Mechanism of bidirectional large deletions 
via annealing between both internal sequences. (C) Mechanism of bidirectional large deletions that involves 
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Figure S1. Complete figures of PA gel heteroduplex assay screening in mouse zygote injection 
samples (related to Figure 1B). * = Samples containing heteroduplex generate extra bands besides 
the WT-sized bands. ^ = Samples that cannot be amplified which was found to have large deletions 































Figure S2. Large deletion outcomes produced after Cas9-mediated breaks. (A) Complete figures of 
large PCR (~1.6 kb) (related to Figure 1C). $ = Samples that were found to have smaller bands 
suggesting large deletions. (B) ~3.2 kb PCR in Ngn3 and Foxp4 founders detected more large 







Figure S3. High cutting efficiency of CRISPR/Cas9-mediated breaks in mouse ES cells. (A) TIDE 
analysis on Ngn3 gRNA-treated samples hardly contained WT alleles (n = 3). (B) RFLP analysis 
using BspMI on Sox1 gRNA-treated samples (n = 4).  (C) RFLP analysis using SacI on Sox3 
gRNA-treated samples (n = 4). (D) RFLP analysis using SmaI on Viperin gRNA-treated samples (n 
= 4). Each gRNA was designed to induce DSB at the corresponding restriction sites. Successful 
cuts should destroy the restriction sites that can be analyzed by restriction endonuclease (RE) 
digestion. Bands indicating the WT alleles (arrows) were clearly present in the negative controls 







Figure S4. Sticky-ended breaks induced by paired Cas9 nickase also generate large deletions. 
Samples from paired-nickase targeting Sox1 (left) or Sox3 (right) were analyzed by qPCR using 
primers located >100 bp away from the breaks. The controls for Sox1 dgRNA Cas9n were samples 








Figure S5. Sequencing and TIDE analyses of samples from SSA trapping experiment. (A) 
Chromatogram of Nprl2-SSA gRNA-treated samples clearly showed the abundance of 43 bp 
deletion as a result of SSA repair. (B) 43 bp deletion in Nprl2-SSA gRNA-treated samples shown 
by TIDE analyses (n = 4). (C) TIDE analyses of Nprl2-out gRNA-treated samples hardly detected 






Table S1. The summary of PA heteroduplex assay and direct Sanger sequencing mutation 





PA gel assay Sequencing of PA+ Sequencing of PA -ve 
+ -ve fail PA+ samples 
sequenced 




Ngn3 15 7 8 0 7 7 8 7 
Foxp4 21 8 10 3 8 8 10 10 
Fzd3 35 20 14 1 15 15 8 8 
Viperin 16 8 8 0 8 8 8 7 
Pik3r6 25 20 5 0 20 20 5 4 
Hmgcs2 25 20 5 0 19 19 4 2 
total 137 83 50 4 77 77 43 38 
 
 





~1.6 kb PCR ~1.6 kb + ~3.2 kb PCR 
Samples with large 
del 
Total large del 
bands 
Samples with large 
del 
Total large del 
bands 
NgN3 15 9 12 12 17 
Foxp4 21 9 9 15 16 
Fzd3 35 10 10 NA NA 
Viperin  16 11 13 NA NA 
Pik3r6 25 5 5 NA NA 
Hmgcs2 25 3 3 NA NA 


















Table S3. List of gRNAs used in zygote injection experiment 
Targets gRNA sequences On-target 
score 
Ngn3 GCACAGCTGGATTCCGGACAAA 56 
Foxp4 CCAGCGTTCCCATTGTCCTT 37 
Fzd3 CTTAGCAAGGGTGTGAAAAG 64 
Viperin GGGTGGCTAGATCCCGGGA 70 
Pik3r6 CTTACCCTGATTGCTCTGGA 56 
Hmgcs2 TACAATCCCTCCTGCTCCCC 39 
Kcnt1 TGCATGAACCGCATGTTGGA 56 


























Targets gRNA sequences On-target 
score 
Ngn3 GCACAGCTGGATTCCGGACAAA 56 
Sox1 GCCGCCGGGCGAGTGCAGGT 56 
Viperin GGGTGGCTAGATCCCGGGA 70 
Sox3 GCTGACCCACATCTGAGCTC 58 
Nprl2-SSA GCACTAGAACCTGATTCAGTT 32 
Nprl2-out GACACTAGAAACCGGAGACCT 61 















Table S5. The primers used in this study.  
Target 
genes 
F primer 5’-3’ R primer 5’-3’ purpose 





Ngn3 TGCTAGTCCTCTCTGGTCTGTG GCTCCCGATCATTGGCCTTC Large 
1.6 kb 
PCR 
Ngn3 TGCTAGTCCTCTCTGGTCTGTG CTCTCTGCCAACAGTCTGCC Large 
3.2 kb 
PCR 
Ngn3 GGGCAGAGCAGATAAAGCGTG CTGCAGTGATGAGACCCAGA Left 
qPCR 
Ngn3 CCCAAACCTCCTTCATGCTA GTTCCTCAAAGAGCCTCGCC Right 
qPCR 
Foxp4 AGTTCAAGGCCATCTGCCAC CACCCAGCCCTTCTAAGTAGC PA gel 
assay 
PCR 
Foxp4 TGGCAGGACAGAGCAAACAG CCTCAATCCTCCTCAGTGGG Large 
1.6 kb 
PCR 
Foxp4 CTGAGGGTTGTTCTCCCACTTC CCTCAATCCTCCTCAGTGGG Large 
3.2 kb 
PCR 
Fzd3 AGGCTGTTCCACATTGGTTC GTGTTTCTCTAAGCAGGGATGT PA gel 
assay 
PCR 
Fzd3 CACACAGAGTATTGTTCGCAG CATCTGCATAAACCCACACTC Large 
1.6 kb 
PCR 





Viperin GTGTTTGCCTGGAATATACCAGTCTTGAGTCCT GACAATCTGCAAGGATTGAATGCTA Large 
1.6 kb 
PCR 
Viperin ACTGAGTCAAGGGAGGTGTTTC GATAGGCACACACCTGCTGCT Left 
qPCR 
Viperin CTACCACTTCACTCGTCAGTGC GTTTGAGCAGAAGCAGTCCTCG Right 
qPCR 










Hmgcs2 AATTGCCACATTATTGGTTGG ACTTCCCTGCTTCCACATTG PA gel 
assay 
PCR 
Hmgcs2 AATCAAGCCACCACTCTTGC CCCTCCCTTTCCTAAGTTGC Large 
PCR 
Kcnt1 CTTCTGTCCTCACAGGCCTGA ACAGAGCCTAGGGAGAGTTTGG Large 
1.6 kb 
PCR 












Sox3 CATCGCTTCGCACTCGCA GCAGGTACATGCTGATCATGTC Left 
qPCR 
Sox3 CGTTGCCTTGTACCGAAGAT CGGGACTTCTCGCTTTTGTAC Right 
qPCR 
Sox1 CCCTTCTCTCCGCTAGGC GTTGTGCATCTTGGGGTTTT RFLP 
analysis 
Sox1 GATCCTGGTTGGCCTTGGTG GTTGTGCATCTTGGGGTTTT Left 
qPCR 
Sox1 CCCTTCTCTCCGCTAGGC GGTGGGTGGAGAGAGGATCA Right 
qPCR 
Nprl2 TTCTTCAGCGAGTTCCACCC TACACCTGGACCGTGTCAAA TIDE 
analysis 
Nprl2 CCCAAGAGAAACACTGGACCAAG CAGTGGTCTACTTTGTGCTTCCA Left 
qPCR 
Nprl2 ATTCCAAGGCGTAGAGGCGATC GGAGTGTGGAAGGCACCTGAT Right 
qPCR 
Sox1 GACTTGCAGGCTATGTACAACATC CCTCTCAGACGGTGGAGTTATATT Internal 
reference 
qPCR 
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Chapter 6:  







6.1. Increasing the efficiency of genome editing 
CRISPR/Cas9 technology has developed rapidly since the first successful modification of 
the mammalian genome [27, 129]. The generation of mutations can now be conducted with 
high efficiency. Chapter 5 has shown that generating genetically modified mice containing 
mutations, such as small indels, is very efficient, with almost all mice containing 
mutations. In Chapter 2, it was shown that the deletion of a large region flanked by two 
gRNAs is less efficient. Deletion of large intervening sequences has been proposed for the 
treatment of diseases that can be cured by such deletions. To translate this strategy into 
clinical practice, it is crucial to improve the efficiency of generating large deletions. This 
low efficiency may be caused by a low delivery efficiency of both gRNAs. Therefore, the 
optimisation of vectors and delivery techniques that can carry all components, including 
both gRNAs, in one vector that enables efficient in vivo delivery should be the next 
investigation priority. Low efficiency of intervening sequence deletion might also be 
caused by prominent NHEJ repair, which could generate indels at both cutting sites 
without snipping out the intervening sequences [41]. Studying the mechanism of large 
intervening sequence deletion, including characterising the molecular factors involved, 
might uncover a strategy to suppress indel NHEJ and increase the efficiency of large 
deletions. The vectors generated in this study described in Chapter 4 may facilitate the 
investigation of the mechanisms involved in the deletion of long intervening sequences, as 
these vectors allow the efficient simultaneous delivery of dual gRNAs. 
Many disease-causing mutations may be repaired using DNA replacement or insertions 
generated through the HDR mechanism. However, as shown in Chapter 2, intentional 
genomic modification by DNA KI is inefficient, which is problematic for therapeutic 
interventions or experiments requiring this approach [8]. Therefore, future studies need to 
address this problem to better utilise CRISPR/Cas9 technology for the seamless correction 





One strategy to increase HDR is to hijack the cellular repair mechanisms to favour HDR 
over NHEJ. These strategies have been tested in studies using inhibitors of NHEJ, such as 
Scr7, NU7441 and KU-0060648, to force the repair mechanisms towards the HDR 
pathway, which involves a DNA end resection step [74-76]. However, some of these 
studies reported no increase in HDR when these inhibitors were used [139, 164]. 
Furthermore, it is possible that these inhibitors could cause adverse effects or toxicity, 
which could create unforeseen problems. 
The study presented in Chapter 5 indicated that DNA end resection occurs frequently and 
can be repaired by an alternative end joining mechanism, resulting in large deletions. 
Despite frequent DNA end resection, the efficiency of donor-templated repair remains low, 
presumably due to a preference for alternative end joining repair rather than donor-
templated repair. Therefore, we need to bear in mind that inhibition of the NHEJ pathway 
might lead to DNA resection, but could possibly result in alternative end joining repair 
outcomes, neglecting the DNA donor provided. Therefore, increasing the KI efficiency 
might require additional inhibition of the alternative end joining pathway. It would be 
interesting to investigate competition between alternative end joining and donor-mediated 
repair in the HDR pathway. 
It is also possible that the abandonment of available donor repair template after DNA end 
resection occurs because the donor DNA is not a suitable template for the repair 
machinery. Therefore, it is also crucial to determine the type of DNA donors preferred by 
the DNA repair system. To date, the most efficient integration is achieved by providing 
ssODN donor with homology arms [35, 50-52]. The use of ssODNs was previously limited 
by the maximum size at which they can be generated (200 nt), which has meant that the 
insertion of longer sequences was not possible. Insertion of longer sequences can now be 





mentioned in Chapter 1 [58-60]. For performing DNA insertion using HITI, it is not 
recommended to use a plasmid to express the gRNA and Cas9, as frequent plasmid 
integration into the break site has been observed, possibly via the same pathway as HITI. 
The plasmid may compete with the donor DNA for insertion into the breaks, thus reducing 
the insertion efficiency. Insertion of long sequences can now be achieved by using long 
ssDNA donor which is generated by the in vitro transcription reverse transcription (iVT-
RT) technique, or is obtained commercially from IDT with its product named Megamer 
ssDNA fragments. This KI approach, known as Easi-CRISPR, has been used to flox an 
exon of mouse gene through zygote injection by inducing two cuts at both floxing sites and 
co-delivery of the long ssDNA donor [56, 57]. Our dual gRNA vectors described in this 
thesis provide tools to help performing floxing strategy using long ssDNA in cell lines due 
to its ability to increase the dual cutting efficiency. 
In this chapter, a strategy to easily generate long DNA donors with single strand homology 
arms, mimicking the ssODN donor homology arms, is proposed. This technique, named 
HD-ADI (heteroduplex donor-assisted DNA integration), is very simple as it involves only 
two PCR amplification steps for the generation of DNA donors. Two sets of PCRs are 
required: the first to amplify the insert sequences, while the second amplifies the insert 
with the addition of homology arm sequences (20–40 nt) to the PCR primers (Figure 6.1). 
The first PCR produces purely insert sequences, while the second PCR produces insert 
sequences flanked by homology arms. The products from the first and second PCRs are 
mixed and slowly re-annealed. This re-annealing should produce four different kinds of 
products; two homoduplex products and two heteroduplex products, in which the latter are 
the dsDNA inserts with single-stranded homology arms (Figure 6.1). Interestingly, 
although it was expected that the donor products that facilitate efficient insertions would be 
the heteroduplexes, the remaining homoduplexes can also act as donor templates. The first 





similar to the HITI method. The second homoduplex from the second PCR could be 
inserted into the DSB via the MMEJ mechanism, similar to the PITCh method (Figure 
6.1). Therefore, the chances of DNA insertions are increased by providing various kinds of 
donor templates for both kinds of repair pathways (NHEJ or HDR). Another advantage of 
this proposed technique compared to Easi-CRISPR is its ability to perform longer 
insertions, since PCR can produce longer inserts than the Easi-CRISPR can generate (~2 
kb). 
The other aspect necessary to consider when trying to increase the efficiency of DNA 
replacement/insertion is to induce the DSB very close to the insertion site [98]. The 
targetable sites of the current commonly used CRISPR SpCas9 system are limited by the 
requirement for a NGG PAM, which limits the available cleavable sites. To broaden the 
targetable regions, other CRISPR systems that recognise various PAM sequences need to 
be expanded and optimised and extensive research to screen or engineer these CRISPR 
systems must be carried out. It is still possible that an RNA-guided endonuclease system 
with a very relaxed, yet highly specific PAM requirement will be found. One study has 
engineered FnCas9 to recognise a relaxed PAM YG, however this engineered Cas9 was 
shown to be inefficient for generating DSB-mediated mutations [108]. 
Another way to undertake efficient mutation correction is by utilising the base editor in 
which dCas9 or Cas9-nickase is attached to cytidine deaminase, as discussed in Chapter 1. 
CRISPR base editing shows great potential to efficiently achieve substitutions without the 
requirement for a repair template and the HDR process, both of which contribute to the low 
efficiency observed when performing substitutions. The base editor could substitute C  T 
with an efficiency of up to 75% in mammalian cells [125, 126]. This is exciting, given that 
the efficiency of HDR using donor template is very low. However, currently the base 
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edited as the current base editor can only edit C  T or G  A. The targetable sites that 
can be edited are also still limited, since the current base editor requires NGG PAM 
sequences, and only edits the targeted base within a small window at positions 4–8 of the 
targeting sequences. It would be an advantage if base editors could choose the bases they 
target flexibly. Therefore, future studies should engineer the current base editor to be able 
to target more a flexible window, and explore the utilisation of the other CRISPR systems 
that have various PAM requirements for their base editor agents. Currently, the most 
efficient base editor can still induce indels at the target sites, and can also induce 
substitutions at unintended sites (off-targets). Future studies must address this problem, for 
example by optimising Base Editor version 2 (BE2), which induces fewer indels, or by 
using other CRISPR systems with high specificity, such as Cpf1 or high fidelity engineered 
Cas9. Shortening the exposure of the base editor in the genome by using RNP delivery 
could also potentially reduce the off-target effects [61]. 
The editing efficiency is strongly affected by the efficiency of the delivery method. It has 
been demonstrated that when CRISPR/Cas9 components are supplied by microinjection or 
performing selections, they exhibit effective cutting activity resulting in mutations in the 
target sequences. Therefore, increased efficiency in therapeutic genome editing can be 
achieved by robust delivery of CRISPR/Cas9 components to the target cells. Delivery of 
CRISPR/Cas9 components for ex vivo therapeutic approaches should be relatively simple, 
as a result of the many effective in vitro delivery techniques available. However, 
challenges arise when performing delivery for in vivo therapeutics. The most promising in 
vivo delivery is by viral vectors, such as the AAV vectors, which have various serotypes. 
Although AAVs can deliver CRISPR/Cas9 components efficiently, studies showing 
successful delivery of CRISPR/Cas9 components using these viral vectors have been 
limited to certain tissues/organs such as the liver, muscle, brain and eye [8, 62]. Further 





tissues/organs, such as the heart and pancreas. The AAV vectors that have been approved 
for clinical use have a restricted packaging capacity of ~4.5 kb, while SpCas9 is ~4.2 kb. 
Therefore, there is limited space remaining to carry the other elements required, such as a 
gRNA expression cassette. This limitation could be tackled by using smaller Cas9 
orthologues, such as SaCas9 [69]. Exploring other RNA-guided nuclease systems with 
smaller sizes, particularly those that are highly efficient and specific with relaxed PAMs 
would be beneficial to improve the delivery and efficiency of this technology for in vivo 
therapeutic genome editing. Investigations could also focus on identifying other viral 
vectors with larger packaging capacity that are non-immunogenic and can infect target 
tissues effectively. Alternative delivery modes should also be considered, such as using 
nanoparticles to deliver the mRNA or protein of interest. This alternative has the advantage 
of transient presence of the nuclease, thus reducing off-target effects that might result from 
constitutive expression of Cas9 [8, 62, 68]. 
 
6.2. Therapeutic genome editing strategies 
An important application of CRISPR genome editing is to cure disease. For genetic 
diseases, correction of the disease-causing mutation to the WT sequence is the ideal 
approach. Genetic correction of point mutations or deletions can be achieved by DNA 
substitutions or insertions. For loss of function diseases, therapeutic transgenes can be 
inserted to a ‘safe harbour’ site to compensate for the loss of protein in a controllable 
fashion. This approach may be more difficult, as it involves the less frequent HDR process. 
Point mutations or small deletions in the exonic region can be corrected more efficiently by 
an exon skipping approach using a large intervening sequence deletion strategy to remove 
the exon containing the mutations. Despite being a more efficient method, the resulting 





deletions can also be used to delete repeat expansions for the treatment of the nucleotide 
expansion disorders such as fragile X syndrome, spinocerebellar ataxia, Huntington’s 
disease and Friedrich’s ataxia, or for diseases caused by duplications [6-8]. The therapeutic 
approach may be simpler for treatments that requires the generation of indel mutations, 
such as knocking out CCR5 for the treatment of HIV infection or the PCSK9 gene to treat 
hypercholesterolemia [69, 138, 141-143]. Therapeutic approaches for the diseases caused 
by dominant gain of function alleles, such as Huntington’s disease, can also utilise efficient 
NHEJ-mediated indel mutations to knock out the mutant allele while retaining the WT 
allele [8]. 
Chapter 3 presented techniques for successful deletion of the Y chromosome using 
centromere removal and chromosome shredding strategies, which can potentially be used 
for the therapy of aneuploidy diseases. This study is the first to show that genome editing 
technologies are capable of deleting an entire chromosome, and to date this is the largest 
deletion (~90 MB) ever reported using genome editing [42]. Moreover, this study resulted 
in the generation of the first XO mouse model via genome editing that could be used as a 
model for Turner syndrome. From this study, we now know that DSBs can induce 
chromosome loss, and that these DSBs may also be the cause of chromosomal losses 
occurring in humans [165]. 
These strategies could be applied for disease modelling and the treatment of diseases 
caused by aneuploidy, which are relatively frequent, occurring in about 1 in 300 live births. 
However, this approach requires further optimisation to determine the best way to delete a 
chromosome. It is hypothesised that shredding the entire chromosome, including the short 
arm, centromere and long arm, will be the ideal way to achieve efficient deletion of the full 
chromosome. Future studies need to study the chromosome deletion in non-dividing cells, 





applications. The centromere removal strategy may not be suitable for non-dividing cells 
as removal of the centromere would result in re-joining between the short and long arms 
and retention of the chromosome. In contrast, the chromosome shredding strategy may 
induce direct chromosome deletion in non-dividing cells. It will also be interesting to 
determine the ideal number of cuts and the cut positions that can induce chromosome 
deletion. It is possible that a small number of cuts in the ideal location could produce more 
efficient chromosome deletion than many cuts in non-ideal positions. This study showed 
that as few as eight cuts in the long arm of the Y chromosome were sufficient for inducing 
efficient chromosome deletion. The cutting sites of gRNA long arm 8X are located 
between positions ~4.3–17.3 MB of a ~90 MB Y chromosome. It may be interesting for 
future studies to examine whether the same number of cuts more widely dispersed such 
that they cover both the long and the short arms of the chromosome would result in more 
efficient deletion in non-dividing cells. Moreover, it is possible that efficient chromosome 
deletion could be achieved by targeting both telomeres for removal, which would 
destabilise the chromosome’s integrity. Future studies could also address the question of 
whether other CRISPR systems, particularly those producing staggered cuts, such as Cpf1, 
could be more efficient for inducing chromosome deletions compared to the SpCas9 
system, which produces blunt cuts. Additionally, it is possible that the chromosome 
fragments may translocate to other chromosome which can cause problems. Therefore, 
further studies need to characterise this possibility. 
The mechanism of chromosome deletion via arm shredding is still unclear. It is puzzling 
how DSBs in the chromosome arms could trigger deletion of the remaining chromosome 
regions. Therefore, future studies also need to study the process and the factors involved in 
chromosome deletion. Understanding this mechanism could help revealing the best way to 





in increased chromosome deletion, while inhibition of DNA end resection factors may 
impede chromosome deletion. 
One aneuploidy disease that could be prioritised for therapy using the chromosome 
deletion approach is Trisomy 21 Down syndrome, which occurs 1 in 700 livebirths. Down 
syndrome is the most common intellectual disability disorder, with many other devastating 
symptoms including congenital heart defects, early-onset Alzheimer’s disease and 
haematopoietic disorders [166]. Some studies have addressed possible strategies to remove 
or silence a copy of Chromosome 21 in cells with trisomy 21. Trisomy correction in cells 
with trisomy 21 can happen naturally, but is rare in vitro. Performing selection by inserting 
a suicide gene, such as the TK gene, to the extra chromosome could simplify the 
identification of cells with euploid chromosomes. However, the selection process is 
complicated, and in vivo application is unlikely to be possible [167]. This in vitro natural 
aneuploidy correction could also be improved by overexpression of the ZSCAN4 protein 
[168]. Another treatment approach for Down syndrome is by methylation silencing of a 
copy of Chromosome 21 by inserting the XIST gene into that chromosome, although this is 
difficult for clinical application [169]. To date no genome editing studies have been able to 
correct trisomy 21. The chromosome deletion strategies presented in this thesis have 
opened an avenue to correct trisomy 21 by deleting one copy of the chromosome. 
However, these approaches will require extensive further study to bring them to real 
application, since there are a number of issues that need to be resolved. The first of these is 
how one copy of a chromosome can be specifically deleted without targeting the remaining 
two copies of Chromosome 21. One solution could be to scan for sequence variations in all 
copies of this chromosome to look for unique target sequences belong to only one copy of 
the chromosome. Furthermore, unlike the mouse or human Y chromosome, which contains 
abundant repetitive sequences, Chromosome 21 may not contain as many repetitive 





Although a set of unique gRNAs can be used to facilitate chromosome deletion, targeting 
repetitive sequences might minimise the number of gRNAs required, which would simplify 
their delivery and increase the efficiency of this approach. Therefore, bioinformatic 
analysis is crucial to help identify repetitive target sequences. The other issues that need to 
be addressed are that assuming a copy of Chromosome 21 could successfully be 
eliminated, how could this be used in clinical applications? What cells/tissues would need 
to be targeted and how could the CRISPR/Cas9 components be delivered to the target 
cells/tissues? Ex vivo trisomy correction of haematopoietic cells and autologous 
transplantation of the corrected cell to the patients might rescue or prevent the 
haematopoietic difficulties faced by Down syndrome patients. Studies have shown that 
CRISPR/Cas9 component could be delivered to neuronal cells in the adult brain by local 
injection of CRISPR/Cas9 AAVs or RNP in vivo [67, 69, 70]. Combining this strategy 
with the chromosome deletion techniques explored here could potentially correct trisomy 
in neuronal cells in the brain, which might rescue aspects of the brain-related abnormal 
phenotype, such as intellectual disability. Overall, extensive consideration and studies are 
necessary to develop this genome editing technology for the therapy of Down syndrome 
and other diseases caused by aneuploidy. 
 
6.3. Concluding remarks 
Overall, the studies in this thesis have contributed to the development and application of 
the CRISPR/Cas9 genome editing platform. Specifically, this thesis describes the 
application of CRISPR/Cas9 genome editing for performing gene swaps in mice to study 
the functional equivalence between two closely related proteins. Strategies were developed 
that allow the deletion of an entire chromosome, which have the potential to model or treat 





to perform experiments requiring simultaneous dual gRNA expression. Finally, in a result 
that is important for other researchers to be aware of, unexpected DNA repair outcomes 
after Cas9 breaks were demonstrated, which may lead false interpretations of edited 
genotypes. 
The current development of CRISPR/Cas applications is still the tip of the iceberg. The 
future of CRISPR genome editing will be very bright, with the rapid development of 
CRISPR systems such as fusions of dCas9 or other catalytically dead RNA-guided 
endonucleases with various enzymatic domains to create tools for various functions. 
Engineered variants of CRISPR systems that recognise different PAM sequences for a 
broad range of targetable regions will also emerge, and many more useful vectors will be 
available to help researchers performing genome editing experiments. We will also see 
many more different applications conducted using CRISPR/Cas technology. This 
technology is predicted to uncover the unprecedented functions of gene(s), particularly 
with the use of CRISPR/Cas9 genome-wide screening. The endonuclease activity of Cas9 
could be utilised for routine diagnostic applications, such as RFLP and Southern blots. 
CRISPR/Cas9-based gene drive will potentially be used to eradicate not only malaria- and 
dengue-carrying mosquitoes but also pest rodents. The ability of CRISPR/Cas9 to easily 
induce DSB will also help scientists to better understand the DNA repair mechanism that 
will eventually uncover the most efficient way to hijack the DNA repair machinery to 
generate predictable repair outcomes. Ultimately, further development of CRISPR/Cas 
technology, together with the advance of gene and stem cell therapy technology, will one 
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